Fused Imidazo [1, 2-a] pyridine

专利摘要:
The present invention provides compounds of the general formula (I) which are useful as anti-ulcer agents:
公开号:KR19990007836A
申请号:KR1019970707359
申请日:1996-04-10
公开日:1999-01-25
发明作者:히로노리 다나까；가즈요시 후꾸주미；다께시 도가와；기미꼬 반노；도시히사 우시로；마사아끼 모리이；다까후미 나까타니
申请人:다나까 테츠오；신니폰 야꾸힝 가부시키 가이샤；
IPC主号:

专利说明:

Fused Imidazo [1, 2-a] pyridine
Peptic ulcers, such as gastric ulcer and duodenal ulcer, have been described as occurring due to the disruption of the balance between aggressive factors (gastric acid, pepsin, etc.) and protective factors (blood flow, mucus, mucosal resistance, mucosal protection, etc.). In general, peptic ulcers are treated medically, and various medications are administered. Drugs for the treatment of peptic ulcers can be classified into two types, one is an inhibitor of aggressive factors and the other is a protective factor promoter, which is appropriately used depending on the type of disease. Recently, histamine H ₂ -blockers (e.g., cimetidine, ranitidine, etc.) are commonly used as inhibitors of aggressive factors at the clinical stage. However, therapeutic resistant ulcers have been reported and H ₂ -blockers have been reported to have adverse effects such as anti-androgen action and inhibitory action on metabolic enzymes in the liver. Recently, H ⁺ / K ⁺ -ATPase (adenosine triphosphatase) has been found to be involved in the final stage of acid secretion, and benzimadazoles, such as omeprazole, which have inhibitory action against this enzyme, are antiulcers. It is proposed to be useful as a sex drug. However, recurrence of ulcers remains an unresolved problem. Other problems that need improvement are also interactions with other agents, for example, reducing the expression of carcinoids and the rate of liver clearance for diazepam and fenitoin. On the other hand, promoters of protective agents exhibit a limited rate of treatment compared to aggressive agents, and it is well known that protective agents slow down the loss of these symptoms. Thus, currently available anti-ulcer drugs are not satisfactory and there is a need for development of better anti-ulcer drugs.
It is an object of the present invention to provide a medicament having an inhibitory action against an aggressive factor and a promoting action against a viscous defense factor, and to provide a better anti-ulcer drug.
European Patent Publication No. 0165545 and US Pat. No. 4,468,400 describe tricyclic compounds having structures similar to the compounds of the present invention. However, there is no description of a compound having the same substituent as the substituent of the compound of the present invention. European Patent Publication Nos. 0033094, 0068378 and 0024 285 describe non-fused imidazo [1,2-a] pyridine, which, due to their antisecretory and cytoprotective action, It was intended to be used for the treatment of ulcers.
The present invention relates to novel fused imidazo [1,2-a] pyridine and a medicament containing the same. More specifically, the present invention is characterized by the use of fused imidazo [1,2-a] pyridine, which has a (hetero) aryl group in the 2-position and an amino group in the 3-position, useful for the treatment of peptic ulcers. Pharmaceutically acceptable salts or solvates thereof, and pharmaceutical compositions containing the same.
In the present invention, after carrying out extensive research, the inventors of the present invention have newly fused imidazo [1,2-a] pyridine having a (hetero) aryl group in 2-position and an amino group in 3-position. It has been found that pharmaceutically acceptable salts or solvates thereof have excellent pharmacological properties and are distinguished from known imidazo [1,2-a] pyridine in terms of pharmacological activity. The present invention is based on such facts.
Accordingly, it is an object of the present invention to provide a novel fused imidazo [1,2-a] pyridine, a pharmaceutically acceptable salt or solvate thereof, which exhibits gastric acid secretion and gastric mucosal protective action.
Another object of the present invention is to provide a pharmaceutical composition containing the above-mentioned fused imidazo [1,2-a] pyridine, their pharmaceutically acceptable salts or solvates as active ingredients.
Compounds of the invention are represented by the following general formula (I):

Wherein ring A and ring B independently of one another represent an aromatic ring selected from benzene, thiophene, furan and pyrrole rings, and R ₁ represents a hydroxyl group, a halogen atom, a lower alkyl group which may be halogenated, a lower alkoxy group or Represents an acyloxy group, R ₂ and R ₃ may be the same or different and each represents a hydrogen atom, an alkenyl group, an acyl group, an alkoxycarbonyl group, or 1) a halogen atom, 2) a hydroxyl group, 3) a lower one A substituent (s) selected from the group consisting of alkoxy group, 4) lower alkylthio group, 5) alkylsulfinyl group, 6) alkoxycarbonyl group, 7) carbamoyl group, 8) alkylamino group and 9) aryl group Represent lower alkyl groups that may have, or R ₂ and R ₃ may form a 5- or 6-membered monocyclic heterocyclic ring together with the nitrogen atom to which they are attached, or R ₂ and R ₃ may represent And an alkylideneamino group or an arylalkylideneamino group together with the nitrogen atom, wherein R ₄ and R ₅ are each independently a halogen atom, cyano group, hydroxyl group, carboxyl group, alkoxycarbonyl group, acyl Substituent (s) selected from the group consisting of an alkylamino group, an aryl group, an acyloxy group, a carbamoyloxy group, or a group consisting of 1) hydroxyl group, 2) lower alkoxy group, 3) aryl group and 4) aryloxy group Lower alkoxy groups which may have a substituent (s) selected from the group consisting of lower alkyl groups which may have, or 1) hydroxyl groups, 2) lower alkoxy groups, 3) lower alkoxycarbonyl groups and 4) aryl groups, Or a lower alkylthio group which may be substituted with an aryl group, k represents 0, 1, 2 or 3, m represents 0, 1 or 2 and n represents 0, 1 or 2 , The dotted line is a solid line with a single bond or represents a double bond, provided that plural R ₄ may be bonded to the same carbon atom.
The terms used in the present specification are defined as follows. Substituents of the compound (I) of the present invention have the following meanings, even if they are present alone or form part of another group.
The benzene, thiophene, furan or pyrrole ring represented by ring A is as follows.

The benzene, thiophene, furan or pyrrole rings represented by ring B are as follows:

The halogen atom may include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
Lower alkyl group means a straight, branched or cyclic alkyl group having 1 to 6 carbon atoms, for example methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, s- Butyl group, t-butyl group, pentyl group, isopentyl group, neopentyl group, t-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 1, 2-dimethylpropyl group, hexyl group, isohexyl group , 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group , 2,3-dimethylbutyl group, 3,3-dimethylbutyl group, 1-ethylbutyl group, 2-ethylbutyl group, 1,2,2-trimethylpropyl group, 1-ethyl-1-methylpropyl group, 1 -Ethyl-2-methylpropyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, 2-methylcyclopentyl group, cyclohex It includes groups and the like. Preferred lower alkyl groups include alkyl groups having 1 to 4 carbon atoms, especially lower aryl groups having 1 to 3 carbon atoms.
Acyl groups include residues of organic acids, such as aliphatic saturated carboxylic acids, aliphatic unsaturated carboxylic acids and arylcarboxylic acids, and specific examples include, for example, formyl groups, acetyl groups, propionyl groups, butyryl groups, isobuty Reyl group, hexanoyl group, bromoacetyl group, trifluoroacetyl group, methoxyacetyl group, butoxyacetyl group, phenoxyacetyl group, 4-bromomethylphenylacetyl group, 4-methoxyphenylacetyl group, 1 -Naphthylacetyl group, 3-pyridylacetyl group, 3-chloropropionyl group, 3-bromopropionyl group, 3- (methylthio) propionyl group, 3-ethoxypropionyl group, 3- (3 , 4-dimethoxyphenyl) propionyl group, 3-carboxypropionyl group, 3-benzoylpropionyl group, 4-chlorobutyryl group, 3-acetylbutyryl group, succinyl group, cyclopentylacetyl group, 6- Bromohexanoyl Lower with a group such as Al Kanon; For example, acryloyl group, 2-furylacryloyl group, crotonoyl group, 3-methylcrotonoyl group, cinnamoyl group, 4-methoxycinnamoyl group, methoxymaleoyl group, methoxy Lower alkenoyl groups having a fumaroyl group and the like; For example, benzoyl group, 4-pentylbenzoyl group, p-anisoyl group, o-anisoyl group, 3,5-bis (trifluoromethyl) benzoyl group, 4-bromobenzoyl group, 4-butoxy Benzoyl group, 4-chlorobenzoyl group, 3-chlorobenzoyl group, 4-chloromethylbenzoyl group, 4-cyanobenzoyl group, 3, 4-dichlorobenzoyl group, 3, 5-dichlorobenzoyl group, 2, 4- Difluorobenzoyl group, 3,4-dimethoxybenzoyl group, 4-ethoxybenzoyl group, 3-fluorobenzoyl group, 4-isopropylbenzoyl group, 3- (trifluoromethyl) benzoyl group, 3,4 , 5-trimethoxybenzoyl group, 3,4-dimethylbenzoyl group, m-toluoyl group, -o-toluoyl group p-toluoyl group, 1-naphthoyl group, 2-naphthoyl group, 1-bro Arylcarbonyl groups having a mo-2-naphthoyl group and the like; Or for example, 2-tenoyl group, 3-tenoyl group, 5-methyl-2-tenoyl group, 2-furoyl group, 5-bromo-2-proyl group, nicotinoyl group, iso Heteroarylcarbonyl groups such as nicotinoyl group, 6-methylpicolinoyl group, 3-methyl-2-benzo [b] furoyl group, quinoline-2-carbonyl groups. Preferred acyl groups are residues of aliphatic carboxylic acids, in particular residues of aliphatic saturated carboxylic acids.
Alkenyl group means a straight or branched alkenyl group having 2 to 6 carbon atoms, for example, vinyl group, allyl group, 1-propenyl group, isopropenyl group, 2-methyl-1-prop Phenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 2-ethyl-1-butenyl group, 3-methyl-2-butenyl group, 1,3-butadienyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 4-methyl-3-pentenyl group, 1-hexenyl group, 2-hexenyl group, 3-hexenyl Group, 4-hexenyl group, 5-hexenyl group, and the like. Preferred alkenyl groups are alkenyl groups having 2 to 3 carbon atoms.
Lower alkoxy groups include alkoxy groups having 1 to 6 carbon atoms, for example methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, s-butoxy group, t-butoxy group, pentyloxy group, isopentyloxy group, neopentyloxy group, t-pentyloxy group, 1-methylbutoxy group, 2-methylbutoxy group, 1,2-dimethylpropoxy group, hex Siloxy group, isohexyloxy group, 1-methylpentyloxy group, 2-methylpentyloxy group, 3-methylpentyloxy group, 1-ethylbutoxy group, 2-ethylbutoxy group, 1,2,2 -Trimethylpropoxy group, 1-ethyl-1-methylpropoxy group, 1-ethyl-2-methylpropoxy group and the like. Preferred alkoxy groups are alkoxy groups having 1 to 4 carbon atoms, in particular alkoxy groups having 1 to 3 carbon atoms.
Lower alkylthio groups include methylthio group, ethylthio group, propylthio group, isopropylthio group, butylthio group, isobutylthio group, s-butylthio group, t-butylthio group, pentylthio group, isopentylthio Group, neopentylthio group, t-pentylthio group, 1-methylbutylthio group, 2-methylbutylthio group, and the like.
Alkylsulfinyl group refers to the above-mentioned alkyl group to which a sulfinyl group is bonded, and may include, for example, methylsulfinyl group, ethylsulfinyl group, isopropylsulfinyl group, butylsulfinyl group, and the like. have.
Lower alkoxycarbonyl group means the lower alkoxy group mentioned above to which a carbonyl group is bonded, for example, methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbon Neyl group, butoxycarbonyl group, isobutoxycarbonyl group, s-butoxycarbonyl group, t-butoxycarbonyl group, pentyloxycarbonyl group, isopentyloxycarbonyl group, 3-methylpentyloxycarbon And an alkyl group, 2,3-dimethylbutoxycarbonyl group, 3,3-dimethylbutoxycarbonyl group, 2-ethylbutoxycarbonyl group, and the like.
The carbamoyl group is carbamoyl group, dimethyl carbamoyl group, ethyl carbamoyl group, diethyl carbamoyl group, allyl carbamoyl group, cyclopentyl carbamoyl group, hexyl carbamoyl group, N- (4-ethoxycarbonyloxy Phenyl) carbamoyl group, N- (4-trifluoromethylphenyl) carbamoyl group, and the like.
Alkylamino groups include methylamino group, ethylamino group, dimethylamino group, diethylamino group, dipropylamino group, N-methyl-N-ethylamino group, N-methyl-N-propylamino group, N-ethyl- N-propylamino group and the like can be included.
Aryl groups include phenyl group, 2-chlorophenyl group, 3-fluorophenyl group, 4-bromo-3-methylphenyl group, 4-methoxyphenyl group, 2-thienyl group, 2-chloro-5-thienyl Group, 3-methyl-2-furyl group, 4-methyl-5-thiazolyl group, 4-chloro2-methyl-5-oxazolyl group, 1-methyl-2-imidazolyl group, 1-bromo- 2-naphthyl group, 6-methyl-2-naphthyl group, 8-methoxy-1-naphthyl group, 3-methyl-2-benzo [b] furyl group, 5-chloro-3-benzo [b] Thienyl groups and the like.
5- or 6-membered cyclic rings formed with nitrogen atoms include, for example, pyrrolyl group, 2-pyrrolinyl group, 3-pyrrolinyl group, pyrrolidinyl group, imidazoryldinyl group, pyrazoli Denyl groups, succinimide groups, piperidino groups, piperazinyl groups, morpholino groups, glutarimide groups, and the like.
The alkylideneamino group includes ethylideneamino group, propylideneamino group, isopentideneamino group, 2-methylpentylideneamino group, 3,3-dimethylbutylideneamino group, 2-ethylbutylideneamino group Etc. may be included.
The arylalkylideneamino group includes a benzylideneamino group, 4-bromobenzylidene amino group, 2-chloro-6-fluorobenzylideneamino group, 2-methylbenzylideneamino group, 4-methylbenzylideneamino group, 2 , 5-dimethylbenzylideneamino group, 2,4,6-trimethylbenzylideneamino group, 3-methoxybenzylideneamino group, 3,4-dimethoxybenzylideneamino group, 2-phenethylideneamino group, ( 1-bromo-2-naphthyl) methylideneamino group, cinnamilideneamino group and the like.
An acyloxy group, carbamoyloxy group or aryloxy group means that an oxygen atom is bonded to the above-mentioned acyl group, carbamoyl group or aryl group, respectively.
The novel compounds of the present invention represented by general formula (I) can be classified into the following two types depending on the partial structure of this compound. That is, when ring B is a benzene ring, the compound of the present invention may be represented by the following general formula (I-1), and when ring B is a thiophene, furan or pyrrole ring, the compound of the present invention may be represented by the following general formula (I -2) can be represented as:


Wherein A, R ₁ , R ₂ R ₃ , R ₄ , R ₅ , k, m and n are defined as above, one of Z ₁ , Z ₂ and Z ₃ is a sulfur, oxygen and nitrogen atom A hetero atom selected from the others, and the rest represent a carbon atom.
Preferred compounds of the present invention represented by general formula (I) include compounds of general formula (I-1) wherein ring B is a benzene ring, or ring B is a thiophene, furan, or pyrrole ring and Z ₁ or Z ₃ is sulfur; Compounds of formula (I-2) which represent hetero atoms selected from oxygen and nitrogen and the rest represent carbon atoms may be included. In particular, ring B preferably represents a benzene or thiophene ring.
Preferred compounds of the present invention represented by general formula (I) may include those in which R ₁ represents a halogen atom, a lower alkyl group which may be halogenated, or a lower alkoxy group. In particular, R ₁ preferably denotes a lower alkyl group having 1 or 2 carbon atoms.
Preferred other compounds of the invention represented by formula (I) may have the same or different R ₂ and R ₃ , each of which is a hydrogen atom, an alkenyl group, or a halogen atom, a lower alkoxy group, a lower alkylthio group and A lower alkyl group which may have a substituent (s) selected from the group consisting of aryl groups, or R ₂ and R ₃ together with the nitrogen atom to which they are attached form a 5- or 6-membered monocyclic heterocyclic ring It can include things you can do. Further preferred compounds are those in which at least one of R ₂ and R ₃ represents a hydrogen atom.
Another preferred compound of the invention represented by formula (I) includes ring A being a benzene, thiophene, furan or pyrrole ring; Ring B is a benzene or thiophene ring; _One of R ₁ is a halogen atom, a lower alkyl group which may be halogenated, or a lower alkoxy group; k is 1 or 2; R ₂ and R ₃ may be the same or different and each may have a ring substituent (s) selected from the group consisting of a hydrogen atom, an alkenyl group, or a halogen atom, a lower alkoxy group, a lower alkylthio group and an aryl group Those which represent lower alkyl groups or where R ₂ and R ₃ together with the nitrogen atom to which they are attached may form a 5- or 6-membered monocyclic heterocyclic ring.
Particularly preferred compounds of the invention represented by formula (I) are those wherein ring A is a benzene, thiophene, furan or pyrrole ring; As shown below, at least one of the substituents of Ring A is located in the ortho-position relative to the binding site to which Ring A is attached to the other part of the molecule comprising the Ring B moiety:

Wherein R ₁ and R ₆ represent a halogen atom, a lower alkyl group which may be halogenated, or a lower alkoxy group; k 'represents 0 or 1; Z represents a hetero atom selected from sulfur, oxygen and nitrogen atoms; Ring B represents a benzene or thiophene ring represented by formula (I-2) wherein Z ₁ or Z ₃ represents a sulfur atom; R ₂ represents a hydrogen atom; R ₃ is a lower alkyl group which may have a substituent (s) selected from a hydrogen atom, an alkenyl group, or a group consisting of a halogen atom, a lower alkoxy group, a lower alkylthio group and an aryl group; The dashed lines represent those double bonds with solid lines.
Most preferred compounds of the invention represented by formula (I) are those wherein ring A is a benzene, thiophene, furan or pyrrole ring; Substituent R ₆ in ring A represented by the above general formula is a lower alkyl group having 1 or 2 carbon atoms; k 'is 0 or 1; Ring B represents a benzene or thiophene ring represented by formula (I-2) wherein Z ₁ is a sulfur atom; R ₂ and R ₃ are each a hydrogen atom; R ₄ and R ₅ are each a halogen atom, a lower alkyl group or a lower alkylthio group; m is 0, 1 or 2; n is 0, 1 or 2; Dotted lines represent double bonds with solid lines.
The following may specifically be mentioned as compounds according to the invention:
3-amino-9-chloro-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline,
3-amino-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline,
3-amino-9-methyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline,
3-amino-5-ethyl-2- (2-methylphenyl) imidazo [2,1-a] -isoquinoline,
3-amino-5-isopropyl-2- (2-methylphenyl) imidazo [2 1-a] -isoquinoline,
3-amino-5-methoxy-2- (2-methylphenyl) imidazo [2,1-a] -isoquinoline,
3-amino-9-methoxy-2- (2-methylphenyl) imidazo [2,1-a] -isoquinoline,
3-amino-2- (2-methylphenyl) -9- (methylthio) imidazo [2,1-a] -isoquinoline,
3-amino-9-fluoro-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] -isoquinoline,
3-amino-2- (4-fluoro-2-methylphenyl) -5-methylimidazo [2,1-a] -isoquinoline,
3-amino-2- (5-fluoro-2-methylphenyl) -9-methylimidazo [2,1-a] -isoquinoline,
3-amino-2- (2-methyl-3-thienyl) imidazo [2,1-a] -isoquinoline,
3-amino-5-methyl-2- (2-methyl-3-thienyl) imidazo [2,1-a] -isoquinoline,
3-amino-2- (2-methyl-3-thienyl) -9- (methylthio) imidazo [2,1-a] -isoquinoline,
3-amino-5-methoxy-2- (2-methyl-3-thienyl) imidazo [2,1-a] -isoquinoline,
3-amino-9-fluoro-5-methyl-2- (2-methyl-3-thienyl) imidazo [2,1-a] -isoquinoline,
3-amino-2- (2-ethyl-3-thienyl) imidazo [2,1-a] -isoquinoline,
3-amino-2- (2,5-dimethyl-3-thienyl) -9-fluoroimidazo [2,1-a] -isoquinoline,
3-amino-2- (2,5-dimethyl-3-thienyl) -5-methylimidazo [2,1-a] -isoquinoline,
3-amino-2- (2,5-dimethyl-3-thienyl) -9-methoxyimidazo [2,1-a] -isoquinoline,
3-amino-2- (5-chloro-2-methyl-3-thienyl) -5-methylimidazo [2,1-a] -isoquinoline,
3-amino-2- (5-ethyl-2-methyl-3-thienyl) -5-methylimidazo [2,1-a] -isoquinoline,
3-amino-2- (2-chloro-3-methyl-4-thienyl) -5-methylimidazo [2,1-a] -isoquinoline,
3-amino-2- (2-methyl-3-furyl) -5-methylimidazo [2,1-a] isoquinoline,
3-amino-2- (2,5-dimethyl-3-furyl) -5-methylimidazo [2,1-a] isoquinoline,
3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-5-ethyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-5,8-dimethyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (4-fluoro-2-methylphenyl) -5-methylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-5-methyl-2- (2-methyl-3-thienyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-8-methyl-2- (2-methyl-3-thienyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-5,6-dimethyl-2- (2-methyl-3-thienyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (4-methyl-3-thienyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2-ethyl-3-thienyl) -5-methylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2-methoxy-3-thienyl) -5-methylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (5-chloro-2-methyl-3-thienyl) -5-methylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2,5-dimethyl-3-thienyl) -5-methylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2,5-dimethyl-3-thienyl) -5-ethylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (5-ethyl-2-methyl-3-thienyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (5-methoxy-2-methyl-3-thienyl) -5-methylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2-chloro-3-methyl-4-thienyl) -5-methylimidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-5-methyl-2- (2-methyl-3-furyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2-methoxy-3-furyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-5-methyl-2- (1-methyl-2-pyrrolyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2,5-dimethyl-3-thienyl) furo [3,2-c] imidazo [1,2-a] pyridine,
3-amino-7- (4-chlorobenzyl) -2- (2-methylphenyl) imidazo [1,2-a] pyrrolo [3,2-c] pyridine,
3-amino-5-methyl-2- (2-methyl-3-thienyl) imidazo [1,2-a] thieno [3,2-c] pyridine,
3-amino-2- (2-chlorophenyl) imidazo [1,2-a] thieno [2,3-c] pyridine,
3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [2,3-c] pyridine,
3-amino-5-methyl-2- (2-methyl-3-thienyl) imidazo [1,2-a] thieno [2,3-c] pyridine,
3-amino-2- (2,5-dimethyl-3-thienyl) imidazo [1,2-a] thieno [2,3-c] pyridine,
3-amino-2- (2,5-dimethyl-3-furyl) -5-methylimidazo [1,2-a] thieno [2,3-c] pyridine,
3-amino-2- (1-methyl-2-pyrrolyl) imidazo [1,2-a] thieno [2,3-c] pyridine,
Suitable pharmaceutically acceptable salts of compounds of general formula (I) include, but are not limited to, conventional salts used in medicaments, for example, alkali metals (eg, sodium, potassium, etc.) or alkaline earth metals (eg, magnesium, calcium, etc.) or Those produced by inorganic bases (such as aluminum), and organic bases (such as ethylamine, propylamine, diethylamine, triethylamine, morpholine, pyridine, piperidine, n-ethylpiperidine, Those produced by diethanolamine, cyclohexylamine, etc.), those produced by basic amino acids (eg lysine, ornithine, etc.), ammonium salts, mineral acids (eg hydrochloric acid, sulfuric acid, phosphoric acid, bromic acid, etc.) Those produced by organic acids (eg, acetic acid, oxalic acid, succinic acid, citric acid, maleic acid, malic acid, fumaric acid, tartaric acid, picric acid, methanesulfonic acid, ethanesulfonic acid, etc.), and acidic amino acids (eg, Glue Acid, might include generated by aspartic acid, etc.).
Compounds of formula (I) according to the invention and pharmaceutically acceptable salts thereof may include solvates thereof (eg water, ethanol, etc.), and polymorphisms if they can be separated.
Compound (I) of the present invention includes stereoisomers, optical isomers or geometric isomers.
Compounds of formula (I) of the present invention can be prepared by a variety of methods. Representative methods are shown below.
(Method 1)

Wherein R ₄ , R ₅ , Z ₁ , Z ₂ , Z ₃ , m and n are as defined above, X is a leaving group to be replaced with an amine, R ₇ is a hydrogen atom, an amino group, a substituent ( Arylalkyl group which may have (s), or an alkyl group which may have a substituent (s).
Among the compounds represented by formula (II), thienopyridine, in which one of Z ₁ , Z ₂ and Z ₃ is a sulfur atom, is a method known to those skilled in the art [see, for example, the Journal of Chemical Society, Perkin Transactions 1, p1390, (1975)] or similar methods. Furopyridine, in which _one of Z ₁ , Z ₂ and Z ₃ in formula (II) is an oxygen atom, is known to those skilled in the art. See, for example, the Journal of Heterocyclic Chemistry, 19, p1207, (1982) or similar methods. Pyrrolopyridine, in which one of Z ₁ , Z ₂ and Z ₃ in formula (II) is a nitrogen atom, is known to those skilled in the art. See, eg, Tetrahedron, 32, p773, (1976 )] Or a similar method. Leaving groups X to be replaced with amines may include, for example, alkoxy groups, alkylthio groups, alkylsulfinyl groups, alkylsulfonyl groups and halogen atoms. Suitable leaving group X is a halogen atom, in particular a chlorine atom.
Among the compounds represented by the general formula (IV) and the like, thienopyridine in which one of Z ₁ , Z ₂ and Z ₃ is a sulfur atom is a method known to those skilled in the art [see, for example, the Journal of Heterocyclic Chemistry, 9, p843, (1972), Journal of Heterocyclic Chemistry, 30, p289, (1993)] or similar methods. Furopyridine in which _one of Z ₁ , Z ₂ and Z ₃ in formula (IV) is an oxygen atom is a method known to those skilled in the art. See, eg, United States Patent No. 4808595, Journal of Heterocyclic Chemistry, 8, p57, (1971), Tetrahedron Letters, p1741, (1977)] or similar methods. In general formula (IV), pyrrolopyridine, in which one of Z ₁ , Z ₂ and Z ₃ is a nitrogen atom, is known to those skilled in the art [see, for example, the Journal of Heterocyclic Chemistry, 29, p359, (19920) or similar methods.
Among the compounds represented by formula (VI), pyrrolo [3,2-c] pyridine, wherein Z 1 is a nitrogen atom, is a method known to those skilled in the art [see, for example, the Journal of Chemical Research. . Synopses, 1, p4, (1986) or references cited therein] or similar methods.
Compound (VI) indicated in Method 1 is Method A (wherein Compound (II) is condensed with Compound (III) by heating (first step) and the resulting Compound (VII) is reduced (second step) Or method B, wherein compound (II) is condensed with compound (III) wherein R ₇ is a hydrogen atom by heating, or method C (here, compound (IV) is subjected to oxidation (first step) The resulting compound (V) can then be prepared according to the amination reaction (second step).
Method A
(1) First step
In the compounds represented by formula (III), suitable R ₇ is an amino group, a methyl group substituted by phenyl having 1 to 3 straight or branched chain alkyl or alkoxy groups having 1 to 4 carbon atoms, or a benzyl group It may include.
The reaction of the compound (II) with the compound (III) may be carried out by an organic solvent, for example, an alcohol [eg, 2-methoxyethanol, etc.], an ether [eg, tetrahydrofuran, diethyl ether, etc.], aromatic Conveniently carried out in hydrocarbons (eg benzene, toluene, xylene, etc.), organic amides (eg, N, N-dimethylformamide, etc.), or other solvents that do not adversely affect the reaction. Preferably, this reaction is carried out at high temperature without solvent.
(2) second stage
The reduction reaction in this step can be hydrocracked in the presence of a catalyst (eg hydrochloric acid, sulfuric acid, Lewis acid, etc., nickel nickel, palladium-carbon, platinum oxide, etc.).
The reaction may be carried out by a solvent such as an organic nitrile [e.g. acetonitrile], an acid [e.g. acetic acid, trifluoroacetic acid etc.], an alcohol [e.g. methanol, ethanol etc.], an ether [e.g. tetrahydrofuran, Diethyl ether, etc.], aromatic hydrocarbons [eg, benzene, toluene, xylene, etc.] organic amides [eg, N, N-dimethylformamide, etc.], or other solvents that do not adversely affect the reaction, or mixtures thereof. Is performed.
The reaction temperature is not critical and generally the reaction is carried out with cooling or heating.
This reaction is completed in 5 minutes to 24 hours.
Method B
This reaction is generally carried out in a sealed reaction tube in an ammonia solution in ammonium hydride or an alcohol (eg methanol, ethanol, etc.).
The reaction temperature is not critical and generally the reaction is carried out with heating to 50 to 200 ° C.
This reaction is completed in 2 to 72 hours.
Method C
(1) First step
Oxidation reactions at this stage may include oxidation by peroxides (eg, inorganic peroxides such as hydrogen peroxide, organic peroxides such as 3-chloroperbenzoic acid, alkylhydroperoxides, peracetic acid, etc.).
The reaction can be carried out by a solvent such as an organic amide [e.g., N, N-dimethylformamide, etc.], an alcohol [e.g., methanol, ethanol, etc.], an ether [e.g., tetrahydrofuran, diethyl ether, etc.], a hydrocarbon [ For example, benzene, toluene, xylene, hexane and the like], organic nitriles [e.g., acetonitrile, etc.], acids [e.g., hydrochloric acid, sulfuric acid, acetic acid, etc.], water, other solvents that do not adversely affect the reaction, or their It is carried out in a mixture.
The reaction temperature is not critical and generally the reaction is carried out with cooling or heating.
This reaction is completed in 5 minutes to 24 hours.
(2) second stage
Aminations applied to this reaction may include reaction with an amination agent [eg, ethanolamine, ammonia, etc.] in the presence of an acylating agent (eg, p-toluenesulfonyl chloride, methanesulfonyl chloride, acetyl glolide, etc.). Can be.
This reaction can be carried out by solvents such as alcohols [eg, methanol, ethanol, etc.], ethers [eg, tetrahydrofuran, diethyl ether, dioxane, etc.], aromatic hydrocarbons [eg, benzene, toluene, xylene, etc.], Halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.), cyclic organic bases (eg, pyridine, picoline, etc.), water, other solvents that do not adversely affect the reaction, or mixtures thereof.
The reaction temperature is not critical and generally the reaction is carried out with cooling or heating.
This reaction is completed in 30 minutes to 48 hours.
Method 2

In the above formula, Ring A, Ring B, R ₁ , R ₄ , R ₅ , k, m and n are as defined above and X 'is a halogen atom.
Aminoisoquinolines represented by formula (VIII) wherein ring B is a benzene ring are known to those skilled in the art [see, for example, Chemical and Pharmaceutical Bulletin, 5, p606, (1975); Heterocycles, 38, p375, (1994); European Patent Publication No. 143001 or a similar method. Among the compounds of general formula (VIII), compounds in which ring B is a thiophene, furan or pyrrole ring can be represented by general formula (VI), the preparation method of which is described in the above-mentioned method 1. 2-halogenoethane represented by the general formula (IX) is a method known to those skilled in the art [see, for example, Japanese Patent Publication (Kokai) No. 152677/86; Journal of Medical Chemistry, 37, p57, (1994)] or similar methods.
Compound (X) or a salt thereof can be prepared by reacting compound (VIII) or a salt thereof with compound (IX).
This reaction can be carried out by solvents such as alcohols [eg, methanol, ethanol, etc.], ethers [eg, tetrahydrofuran, diethyl ether, etc.], aromatic hydrocarbons [eg, benzene, toluene, xylene, etc.], halogenated hydrocarbons [ For example, dichloromethane, chloroform, etc.], organic amides (eg, N, N-dimethylformamide, etc.) or other solvents that do not adversely affect the reaction.
The reaction can be carried out with inorganic or organic bases, for example alkali metal hydroxides [eg, sodium hydroxide, potassium hydroxide, etc.], alkali metal carbonates [eg, sodium carbonate, potassium carbonate, etc.], alkali metal bicarbonates [eg, bicarbonates]. Sodium, potassium bicarbonate and the like], trialkylamine [eg, trimethylamine, triethylamine and the like], pyridine or lutidine and the like.
The reaction temperature is not critical and generally the reaction is carried out at room temperature or with heating.
This reaction is completed in 30 minutes to 24 hours.
Compounds represented by general formula (X) can also be prepared by modifying the partial structure of compound (X) with appropriate substituents in a suitable manner. For example, target compounds may be substituted with halogens such as chlorine, bromine and the like with nitriles. Shin jikken kagaku kouza; Maruzene company: Japan, 14, p 1437] or cross-coupling to convert halogens such as chlorine, bromine and the like into alkyl groups such as methyl, ethyl and the like or aryl groups such as phenyl and naphthyl [Synthesis, p317, (1985)], or hydrolyze nitriles to carboxylic acids and derivatives thereof [Organic Syntheses, 2, p588, (1943)], or convert nitriles to acyl groups using organometallic reagents [Journal of Chemical Society , p4566, (1965)] or protection and deprotection with hydroxy or amino groups [W. Greene, Protectiive Groups in Organic Synthesis, reduction of nitro groups to amino groups, reduction of carboxylic acids or derivatives thereof to hydroxymethyl groups, alkylation of hydroxy or amino groups, or diazonium amino groups It can be obtained according to the reaction of converting to alkylthio or arylthio group via salt (Journal of the American Chemical Society, 82, p2872, (1960)).
Compound (Ia) or a salt thereof can be prepared by subjecting compound (X) or a salt thereof to the nitration reaction (first step), followed by reduction (second step) of the compound obtained.
(1) First step
Suitable nitrating agents that can be used in this reaction include alkali metal nitrite salts (eg sodium nitrite, potassium nitrite, etc.), or nitrite esters (eg t-butyl nitrite, phenyl nitrite, isopentyl nitrite, etc.). ] May be included.
This reaction can be carried out in a solvent such as an organic amide [e.g., N, N-dimethylformamide, etc.], an alcohol [e.g., methanol, ethanol, etc.], an ether [e.g., tetrahydrofuran, diethyl ether, dioxane, etc.] , Hydrocarbons (eg benzene, toluene, xylene, hexane, etc.), organic nitriles (eg, acetonitrile, etc.), acids [eg, hydrochloric acid, sulfuric acid, acetic acid, etc.], water, other solvents that do not adversely affect the reaction, Or mixtures thereof.
The reaction temperature is not critical and generally the reaction is carried out with cooling or heating.
This reaction is completed in 5 minutes to 6 hours.
(2) second stage
Reduction reactions that can be applied to this reaction include the use of catalytic reduction in the presence of a catalyst (eg palladium-carbon, platinum oxide, etc.) or a combination of metals (eg titanium, iron, zinc, etc.) with hydrochloric acid, acetic acid, propionan, etc. It may include reducing.
This reaction may be carried out by a solvent such as an organic amide [eg, N, N-dimethylformamide, etc.], an alcohol [eg, methanol, ethanol, etc.], an ether [eg, tetrahydrofuran, diethyl ether, dioxane, etc.] , Hydrocarbons [eg, benzene, toluene, xylene, hexane, etc.], organic nitriles [eg, acetonitrile, etc.], acids [eg, hydrochloric acid, sulfuric acid, acetic acid, etc.], water, other solvents that do not adversely affect the reaction, Or mixtures thereof.
The reaction temperature is not critical and generally the reaction is carried out with cooling or heating.
This reaction is completed in 5 minutes to 24 hours.
(Method 3)

In the above formula, Ring A, Ring B, R ₁ , R ₄ , R ₅ , k, m and n are as defined above and X 'is a halogen atom.
The 3,4-dihydroisoquinoline represented by the general formula (XI) in which ring B is a benzene ring is known by those skilled in the art [see, for example, Japanese Patent Publication (Kokai) No. 213870/93 or references cited therein or the like. Compounds represented by formula (XI) wherein ring B is a thiophene, furan or pyrrole ring can be prepared by methods known to those skilled in the art (see, eg, Journal of Medical Chemistry, 31, p641, (1988); Journal of Chemical Research Synopses, 2, p4, (1986) or references cited therein] or similar methods.
5,6-dihydroimidazopyridine represented by general formula (XII) reacts compound (XI) with compound (IX) (first step), and then introduces the resultant compound into reaction with ammonium salt ( Step 2).
(1) First step
The reaction can be carried out by a solvent such as ether [eg, tetrahydrofuran, diethyl ether, dioxane, etc.], hydrocarbon [eg, benzene, toluene, xylene, hexane, etc.], halogenated hydrocarbon [eg, dichloromethane, chloroform Etc.], organic amides (eg, N, N-dimethylformamide, etc.) or other solvents that do not adversely affect the reaction.
The reaction temperature is not critical and generally the reaction is carried out at room temperature or with heating.
This reaction is completed in 30 minutes to 24 hours.
(2) second stage
Suitable ammonium salts used in this reaction include inorganic ammonium salts (eg, ammonium carbonate sulfate, etc.) or organic ammonium salts (ammonium formate, ammonium acetate, etc.).
This reaction can be carried out in a solvent such as an organic amide [eg, N, N-dimethylformamide, etc.], an alcohol [eg, methanol, ethanol, etc.], an ether [eg, tetrahydrofuran, diethyl ether, dioxane, etc.] , Hydrocarbons (e.g., benzene, toluene, xylene, hexane, etc.), organic nitriles (e.g., acetonitrile, etc.), acids [e.g., hydrochloric acid, sulfuric acid, acetic acid, etc.], water, and other solvents that do not adversely affect the reaction. Is performed.
The reaction temperature is not critical and generally the reaction is carried out at room temperature or with heating.
This reaction is completed in 30 minutes to 24 hours.
Compounds represented by the general formula (XII) can also be prepared by converting the partial structure of the compound (XII) with appropriate substituents in the manner exemplified above.
Compound (Ib) or a salt thereof of Method 3 may be prepared from Compound (XII) in a similar manner to the preparation of Compound (Ia) or a salt thereof from Method (X) or a salt thereof in Method 2.
Compound (X) or a salt thereof of Method 3 may also be prepared by subjecting compound (XII) or a salt thereof to the oxidation reaction.
Oxidation reactions applied to this reaction may include dehydrogenation in the presence of a catalyst (eg, platinum, palladium-carbon, precipitated alumina-chromium oxide, copper, nickel, etc.).
The reaction solvent may include, for example, diphenyl ether, diphenylmethane, benzene, toluene, naphthalene, tetralin, decalin and the like. This reaction can be carried out without solvent.
Although not critical, a high reaction temperature is required, which is usually carried out with heating.
This reaction is completed in 30 minutes to 24 hours.
Compound (Ib) or a salt thereof can also be prepared by introducing compound (Ia) or a salt thereof into the reduction reaction.
Reduction reactions applied to this reaction may include catalytic reduction in the presence of a catalyst (eg, palladium-carbon, platinum oxide, etc.).
This reaction can be carried out by solvents such as alcohols [eg, methanol, ethanol, etc.], ethers [eg, tetrahydrofuran, diethyl ether, dioxane, etc.], aromatic hydrocarbons [eg, benzene, toluene, xylene, etc.], Organic amides (eg N, N-dimethylformamide, etc.) or other solvents that do not adversely affect the reaction.
Although the reaction temperature is not critical, the reaction is preferably carried out at room temperature or at the boiling point of the solvent used.
This reaction is completed in 30 minutes to 72 hours.
(Method 4)

Wherein, ring A, ring B, R ₁ , R ₄ , R ₅ , k, m and n are as defined above, R ₈ is a hydrogen atom, a lower alkoxy group, an alkenyl group, or a halogen atom, A lower alkyl group which may have a substituent (s) selected from a oxy group, a lower alkoxy group, an alkylthio group, an alkylsulfinyl group, an alkoxycarbonyl group, a carbamoyl group, an alkylamino group and an aryl group, and R ₉ and R ₁₀ may be the same or different and each may have a substituent (s) selected from a hydrogen atom, a lower alkoxy group, an alkenyl group, or a halogen atom, an alkoxycarbonyl group, a carbamoyl group, an alkylamino group and an aryl group Lower alkyl group.
Compound (Id) or a salt thereof may be prepared by introducing compound (Ic) or a salt thereof into acylation.
Acylating agents used in this reaction may include the desired carboxylic acid, anhydrous carboxylic acid, acyl halide or one of these compounds in combination with a suitable condensing agent.
This reaction can be carried out by solvents such as cyclic organic bases [eg, pyridine and the like], alcohols [eg, methanol, ethanol and the like], ethers [eg, tetrahydrofuran, diethyl ether, dioxane and the like], hydrocarbons [eg , Benzene, toluene, xylene, hexane, etc.], halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.), organic amides (eg, N, N-dimethylformamide, etc.) or other solvents that do not adversely affect the reaction. Is performed.
The reaction temperature is not critical and generally the reaction is carried out with cooling or heating,
This reaction is completed in 5 minutes to 6 hours.
Compounds (If), (Ig) and (Ie) or salts thereof can be prepared by introducing compounds (Ic), (If) and (Id) or salts thereof into alkylation.
The alkalizing agent used in this reaction may include the desired halogenated alkyl, halogenated aryl alkyl or halogenated alkenyl.
This reaction is generally carried out in the presence of a base.
Suitable bases include inorganic bases such as alkali metal hydrides [eg, sodium hydride, potassium hydride, etc.], alkali metal hydroxides [eg, sodium hydroxide, potassium hydride, etc.], alkaline earth metal hydroxides [eg, magnesium hydroxide, Calcium hydroxide, etc.], alkali metal carbonates [eg, sodium carbonate, potassium carbonate, etc.], alkaline earth metal carbonates [eg, magnesium carbonate, calcium carbonate, etc.], alkali metal bicarbonates [eg, sodium bicarbonate, potassium bicarbonate, etc.], Alkaline earth metal phosphates [eg, magnesium phosphate, calcium phosphate, etc.], alkali metal acetates [eg, sodium acetate, potassium acetate, etc.], and organic bases such as trialkylamines [eg, trimethylamine, trimethylamine, etc.] , Pyridine, pyrroline, N-methylmorpholine, N-methylpyrrolidine and the like.
This reaction can be carried out by solvents such as alcohols [eg, methanol, ethanol, etc.], ethers [eg, tetrahydrofuran, diethyl ether, dioxane, etc.], hydrocarbons [eg, benzene, toluene, xylene, hexane, etc.], Organic amides (eg, N, N-dimethylformamide, etc.) or other solvents that do not adversely affect the reaction.
Although the reaction temperature is not critical, the reaction is preferably carried out at room temperature or at the boiling point of the solvent used.
This reaction is completed in 5 minutes to 24 hours.
Compounds (If) and (Ig) or salts thereof can also be prepared by introducing compounds (Id) and (Ie) or salts thereof into the reduction reaction.
Suitable reducing agents used in this reaction may include lithium aluminum hydride and the like.
This reaction may be a solvent, for example ether [e.g., tetrahydrofuran, diethyl ether, dioxane, etc.], a hydrocarbon [e.g., benzene, toluene, xylene, hexane, etc.] or other solvent that does not adversely affect the reaction. Is performed.
Although the reaction temperature is not critical, the reaction is carried out with cooling or heating.
This reaction is completed in 5 minutes to 24 hours.
(Method 5)

Wherein, ring A, ring B, R ₁ , R ₄ , R ₅ , R ₈ , k, m and n are as defined above.
Compound (Ih) or a salt thereof can also be prepared by subjecting compound (Ic) or a salt thereof and the desired aldehyde to a dehydration reaction.
This reaction is generally carried out with solvents such as alcohols [eg, methanol, ethanol, etc.], ethers [eg, tetrahydrofuran, diethyl ether, dioxane, etc.], aromatic hydrocarbons [eg, benzene, toluene, xylene, etc. ], Halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.) or other solvents that do not adversely affect the reaction, or without solvent.
Inorganic bases such as alkali metal hydroxides [eg, sodium hydroxide, potassium hydroxide, etc.], inorganic acids [eg, hydrochloric acid, sulfuric acid, etc.] or Lewis groups [eg, toluenesulfonic acid, zinc chloride, boron trifluoride, etc.] are catalyzed Can be used as.
Although the reaction temperature is not critical, the reaction is preferably carried out with cooling or heating in general.
This reaction is completed in 5 minutes to 24 hours.
Compounds (If) or salts thereof can also be prepared by incorporating compound (Ih) or salts thereof in a reduction reaction.
Reduction reactions applied to this reaction may include reduction with a hydroxide complex (eg sodium borohydride) and catalytic reduction in the presence of a catalyst (eg palladium-carbon, platinum oxide, etc.).
This reaction can be carried out by solvents such as alcohols [eg, methanol, ethanol, etc.], ethers [eg, tetrahydrofuran, diethyl ether, dioxane, etc.], aromatic hydrocarbons [eg, benzene, toluene, xylene, etc.], Organic amides (eg N, N-dimethylformamide, etc.) or other solvents that do not adversely affect the reaction.
Although the reaction temperature is not critical, the reaction is preferably carried out at room temperature or at the boiling point of the solvent used.
This reaction is completed in 5 minutes to 24 hours.
Suitable salts of compounds (Ia)-(Ih), (X) and (XII) are the acid addition salts exemplified for compound (I).
Compounds represented by formula (I) may also be prepared by converting the partial structure of compound (I) with appropriate substituent (s) using the methods exemplified in part above.
The intermediates and target compounds obtained in the above methods are separated and purified using a separation method conveniently used in the field of organic synthetic chemistry, for example, filtration, extraction, washing, concentration, drying, recrystallization, various chromatography, and the like. Can be. The intermediate may be used for the next step of the reaction without further purification.
If the salt of compound (I) is intended to be obtained and compound (I) is produced in salt form, it can be purified appropriately. When compound (I) is produced in free base form, salts can be obtained by adding an acid to a solution or suspension of compound (I) in a suitable organic solvent. Compound (I) and pharmaceutically acceptable salts thereof may also be present as adducts with the water or solvent used. Such additives are included in the present invention.
The compounds of the present invention represented by general formula (I) are shown in Tables 1 and 2. The compound number is according to the description later. The compound represented by general formula (I-1) is shown in Table 1, and the compound represented by general formula (I-2) is shown in Table 2. For the convenience of the reader, the general formulas (I-1) and (I-2) shown with position numbers are shown below.

In Table 1 and Table 2, substituents are often abbreviated, as follows.
Memethyl group Pip piperidino group
Et ethyl group Mor morpholino group
Prn-propyl group Suc succinimide group
i-Pr isopropyl group Phhphenyl group
Bun-butyl group Pyr pyrrolyl group
Penn-pentyl group Fufuryl group
i-Pen isopentyl group Th thienyl group
c-Pen cyclopentyl group Naph naphthyl group
Hexn-hexyl group Bzfu benzo [b] furyl group
Acacetyl group
In Table 1 and Table 2, the numbers in parentheses indicate the position at which ring A is bonded at the 2-position, and the numbers and substituents in braces are shown where substituent R ₁ is located at ring A.
In addition, the numbers in parentheses indicate the position at which the other group on the aryl group is bonded, and the numbers and substituents in the braces indicate the position and nature of the substituent on the aryl group. Some examples follow.

In columns 5-6 of Tables and Table 2, DB means that the dashed lines in formulas (I-1) and (I-2) represent double bonds between the 5- and 6-positions with solid lines, SB It means a single bond.

TABLE 1
Examples of compounds according to the invention represented by general formula (I-1)








TABLE 2
Examples of compounds according to the invention represented by general formula (I-2)





In order to show the excellent inhibitory action against gastric acid secretion and the superior protective action against gastric mucosa of the compounds of the present invention, pharmacological and acute toxicity tests were carried out using experimental animal models as follows. In Table 3, Table 4, Table 5, Table 6 and Table 7, the numbers of the test compounds correspond to the compound numbers in Tables 1 and 2.
Experimental Example 1. Inhibitory effect on H ⁺ / K ⁺ -ATPase activity
According to the method of Hongo et al (The Journal of Pharmacology, 52, p295, (1990)), microsomal fractions prepared from porcine gastric mucosa were used as standard enzymes. Test enzyme (0.1-100 μM) dissolved in standard enzyme (protein 10-20 μg) and dimethylsulfoxide was added at 37 ° C. in 50 mM Tris-acetate buffer (pH 7.4, 2 mM magnesium chloride, 5 mM potassium chloride). Incubate for 30 minutes. The enzyme reaction was initiated by the addition of adenosine triphosphate (ATP) tris at a final concentration of 2 mM and the reaction was held at 37 ° C. for 15 minutes. The reaction was terminated by adding cold 10% trichloroacetic acid. The inorganic phosphate released during the reaction was measured by colorimetric quantitation according to Fiske-Subbarow's method [The Journal of Biological Chemistry, 66, p375, (1925)]. H ⁺ / K ⁺ -ATPase activity was determined by the difference in enzyme activity under and without potassium chloride. The inhibitory activity of the test compound was determined as a 50% inhibitory concentration (IC 50 value) from the response-concentration curves and the results are shown in Table 3.
TABLE 3
Inhibitory effect on H ⁺ / K ⁺ -ATPase activity


Experimental Example 2 Inhibition of Gastric Acid Secretion Observed Under Acute Fistula Method
Male Wistar rats (6-8 weeks) were starved for 24 hours (water was eaten at random). Rats were anesthetized by intraperitoneal administration of 1.25 g / kg urethane. The abdomen was dissected and the acute gastrointestinal was connected to the stomach. 2 ml of saline was injected into the stomach and recovered every 20 minutes. Gastric acid secretion was determined by titrating gastric fluid to pH 7.0 with 150 mM sodium hydroxide using an automatic titrator. Test compound (30 mg / kg) suspended in aqueous sodium carboxymethylcellulose (CMC-Na) solution (0.5%) was administered in the duodenum. After 1 hour, histamine dihydrochloride (10 mg / kg) dissolved in saline was administered subcutaneously to promote gastric acid secretion. The cumulative gastric acid secretion during 2 hours after promotion with histamine was calculated and this amount was compared with the cumulative amount of the control group to determine inhibition of gastric acid secretion (%). In the control group, only 0.5% CMC-Na aqueous solution was administered in the duodenum. The test results are shown in Table 4.
TABLE 4
Suppression of gastric acid secretion observed under acute fistula

Experimental Example 3 Inhibition of Gastric Acid Secretion Observed Under Stomach Perfusion Method
Male Sprague Dawrey rats (6-7 weeks) were starved for 24 hours (water randomly fed). Rats were anesthetized by intraperitoneal administration of 1.25 g / kg urethane. The abdomen was dissected and saline was perfused intraperitoneally during the experiment. Perfusion was titrated with 10 mM sodium hydroxide to pH 5.5 using an operating titrator according to the Statmethod. Histamine dihydrochloride (8 mg / kg / hr) was administered intravenously to promote gastric acid secretion. Two hours after promotion with histamine, test compound (1-10 mg / kg) was administered intraperitoneally. The test compound was mixed with a small amount of Polysorbate-80 and the mixture suspended in brine. Test compounds were evaluated using ID ₅₀ (dose representing 50% inhibition of gastric acid secretion) calculated on the basis of inhibition of gastric acid secretion observed 1 hour after test compound administration. The test results are shown in Table 5.
TABLE 5
Suppression of gastric acid secretion observed under gastrointestinal perfusion

Experimental Example 4. Ethanol-induced gastric injury inhibition (gastric mucosa protection)
Male Wistar rats (6-7 weeks, 5 per group) were used that were starved for 24 hours (water was eaten at random). Test compounds (30 mg / kg) suspended in CMC-Na aqueous solution (0.5%) were administered orally. The control group was administered with only 0.5% CMC-Na aqueous solution. 30 minutes after administration, the stomach was injured by oral administration of 0.5 ml of ethanol per 100 g body weight. After 1 hour, rats were killed with excess ether and the stomach was removed and fixed with 2% formalin. After fixation, the stomach was dissected along the large curve. The size of each mucosal injury was measured under an anatomical microscope and the total damage size of each rat was determined and used as the ulcer index (mm). The rate of inhibition of gastric injury was determined by comparing the ulcer indices of the control and test groups. The test results are shown in Table 6.
TABLE 6
Ethanol-induced gastric injury suppression


Experimental Example 5. Acute Toxicity
Male ICR mice starved for 16 hours (water is eaten arbitrarily) (6 weeks, 3 dogs per group) orally administered test compound suspended in 5% arabic gum solution. Was determined and the approximate lethal dose was determined.
TABLE 7
Acute toxicity


By the above experiments, it was found that the compound of the present invention has H ⁺ / K ⁺ -ATP activity and gastric acid secretion inhibitory action and gastric mucosa protective action. In addition, the compounds of the present invention showed low toxicity.
Accordingly, the present invention provides an excellent anti-ulcer drug having an inhibitory action against aggressive factors and a promoting action against protective factors. Therefore, the anti-ulcer agents of the present invention are useful for the treatment and prevention of gastric-duodenal ulcer, gastritis, reflux esophagitis, Zolinger-Erison syndrome, and the like.
Pharmaceutical compositions containing, as active ingredient, one or more compounds of the present invention or pharmaceutically acceptable salts or solvates thereof may be used as medicaments mentioned above. The pharmaceutical composition can be administered orally or transdermally in the form of tablets, powders, granules, capsules, pills, syrups, suppositories, injections, external preparations, infusions, and the like. This pharmaceutical composition can be prepared without difficulty by conventional methods. For example, conventional methods can be prepared using other additives used for oral use. Examples of the carrier may include lactose, corn starch, sucrose, glucose, crystalline cellulose, silica, sorbitol, and the like. Examples of the binder may include polyvinyl alcohol, polyvinyl ether, ethyl cellulose, gum arabic, tragacanth, gelatin, hydroxypropyl cellulose, hydroxypropyl starch, polyvinylpyrrolidone and the like. Examples of disintegrants may include starch, agar, gelatin, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, calcium carboxymethylcellulose, dextran and the like. Examples of lubricants may include magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oils, and the like. The colorant may be selected from those that are approved for the manufacture of a medicament. Examples of corrective agents may include cocoa powder, mentha oil, cinnamon powder, and the like. Tablets and granules can be coated with libido, gelatin and the like. Injectables can be readily prepared by conventional methods using distilled water, pH-adjusting agents, buffers, stabilizers, solubilizers, and other commonly used additives as needed.
When using a compound of the present invention as an anti-ulcer drug, the dosage will vary depending on environmental conditions, such as the condition, age, weight and route of administration of each patient. Dosages may be generally from 3 to 1,500 mg, preferably from 5 to 800 mg per day for adults. Increasing or reducing the dosage may also be tolerated and may be administered once daily or in divided portions.
The compounds of the present invention can be conveniently administered for a long time, for example for a week or longer.
Pharmaceutical compositions containing a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, useful for the treatment of the above-mentioned diseases include one or more pharmacologically active ingredients, for example antacids (magnesium carbonate, hydroxide). Magnesium, aluminum hydroxide, magnesium aluminate, etc.), non-steroidal anti-inflammatory agents (such as indomethacin, aspirin, naproxen), steroids, nitrite disinfectants (ascorbic acid, aminosulfonic acid, etc.), antibiotics (penicillin, tetracycline) And the like, and optionally, enzymes, vitamins or amino acids.
Other substances which inhibit acid secretion to enhance the main action and / or eliminate or reduce side effects in the additive or superadditive concept of compounds according to the invention, for example H ₂ blockers (cimetidine or Ranitidine, etc.) or so-called peripheral anticholinergic agents (such as pyrenezepine, tellenezepine or zolezepine) or in combination with antibacterial substances (cephalosporin, tetracycline, nalidixic acid, etc.) to eradicate Helicobacter pyrroli. Should be interested
Best Mode for Carrying Out the Invention
The present invention will be described in more detail through examples. However, the present invention is not limited thereto. Starting compounds used in the present invention include novel compounds. Such starting compounds are also described in the preparation examples below. In Preparation Examples and Examples, IR means Infrared spectrum, data is shown using cm ⁻¹ units, and the method used is shown in parentheses. MS stands for mass spectrum, HRMS stands for high-resolution mass spectrum, and the method used is shown in parentheses. NMR means proton nuclear magnetic resonance spectra, data are given in ppm and solvents used are shown in parentheses using the following abbreviations.
CDCL chloroform-d
DMSO dimethylsulfoxide-d ₆
ACET acetone-d ₆
MEETH Methanol-d ₄
Preparation Example 1
4- (4-methoxybenzyl) amino-6-methylthieno [3,2-c] pyridine
To a 5.1 g solution of sodium hydride (pre-decanted with hexane) in an oil in 60 ml of anhydrous tetrahydrofuran was added dropwise 30 g of triethyl 2-phosphonopropionate at room temperature for 30 minutes in a dry argon atmosphere. It was. After further stirring the mixture for 1 hour, a 11.8 g solution of 2-thiophenaldehyde in 30 ml of tetrahydrofuran was added dropwise. The mixture was stirred at rt for 2 h. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed successively with water and saturated brine and then dried over anhydrous magnesium sulfate. The dry layer was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give 11.0 g of a yellow oil of ethyl 2-methyl-3- (2-thienyl) acrylate. Then 150 ml of ethanol and 60 ml of 2N aqueous sodium hydroxide solution were added to the oil and the mixture was refluxed for 1 hour. After cooling, ethanol was removed under reduced pressure and the residue acidified with dilute hydrochloric acid. Filtration collected crystalline precipitate to give 8.2 g of a white powder of 2-methyl-3- (2-thienyl) acrylic acid.
To a mixture of 8.2 g of 2-methyl-3- (2-thienyl) acrylic acid and 9.5 ml of triethylamine in 45 ml of acetone, 7.2 ml of ethyl chlorocarbonate was added dropwise over 30 minutes under stirring and ice cooling. After stirring for 1 hour, a solution of 5.1 g of sodium azide in 10 ml of water was added dropwise for 30 minutes, followed by stirring for 1 hour. The reaction mixture was poured into water and extracted with benzene. The extract was washed with water and saturated brine and then dried over anhydrous sulfuric magnesium. The drying agent was filtered off and the solvent was removed under reduced pressure, and then 15 ml of diphenyl ether was added to the residue. To the obtained solution was added dropwise a mixture of 14 ml of tri-n-butylamine and 35 ml of diphenylether at 200 ° C. After the addition was complete the reaction mixture was cooled and the crystalline precipitate was washed with diethyl ether to give 6.2 g of a pale yellow powder of 6-methylthieno [3,2-c] pyridin-4 (5H) -one.
A 6.2 g solution of 6-methylthieno [3,2-c] pyridin-4 (5H) -one in 30 ml of phosphoryl chloride was heated at reflux for 1 hour. After cooling excess phosphoryl chloride was removed under reduced pressure and the residue was poured into ice water, basified with 2N aqueous sodium hydroxide solution and extracted with chloroform. The extract was washed successively with water and saturated brine and then dried over anhydrous magnesium sulfate. The drying agent was filtered off and the solvent was removed under reduced pressure to yield 7.0 g of a brown oily substance of 4-chloro-6-methylthieno [3,2-c] pyridine.
A mixture of 7.0 g of 4-chloro-6-methylthieno [3,2-c] pyridine and 28 ml of 4-methoxybenzylamine was stirred at 170 ° C. for 4 hours. After cooling, the reaction mixture was diluted with 400 mL of chloroform, washed with water and saturated brine and dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel, column chromatography to give 10 g of a yellow oily substance of the title compound.

Preparation Example 2
4-amino-6-methylthieno [3,2-c] pyridine
To a 24 g solution of 4- (4-methoxybenzyl) amino-6-methylthieno [3,2-c] pyridine in 80 ml of trifluoroacetic acid was added 15 ml of concentrated hypoamic acid and the mixture was stirred at ambient temperature for 30 minutes. . The reaction mixture was poured into ice water, basified by addition of 28% ammonia water and extracted with chloroform. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography and recrystallized from chloroform / petroleum ether to give 15 g of a white powder of the title compound.

Preparation Example 3
7-aminothieno [2,3-c] pyridine
A small amount of 33 g of 3-chloroperbenzoic acid was added to an 18 g solution of thieno [2,3-c] pyridine in 300 ml of chloroform over an hour with ice cooling, followed by stirring for a further 1 hour under the same conditions. The reaction mixture was diluted with 400 ml of chloroform and washed successively with water, saturated sodium carbonate solution and saturated brine and dried over anhydrous magnesium sulfate. The drying agent was filtered off and the solvent was removed under reduced pressure to give 16.6 g of a white powder of thieno [2,3-c] pyridine-N-oxide.
To a solution of 16.6 g of thieno [2,3-c] pyridine-N-oxide in 500 ml of chloroform, 25 g of p-toluenesulfonyl chloride was added in small portions with ice cooling for 1 hour. After the reaction mixture was stirred for an additional 30 minutes under the same conditions, 250 ml of 10% aqueous ammonia was added and stirred for 16 hours at ambient temperature. The reaction mixture was diluted with 400 ml of chloroform, washed with water and saturated brine and dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give 2.8 g of a brown oily material of the title compound.

Preparation Example 4
1-amino-8-chloro-7-methoxyisoquinoline
To a 1.3 g solution of 8-chloro-7-methoxyisoquinoline-N-oxide in 40 ml of pyridine was added 1.4 g of p-toluenesulfonyl chloride and the mixture was stirred at ambient temperature for 2 hours. The solvent was evaporated under reduced pressure and 20 mL of ethanolamine was added to the resulting residue and the mixture was stirred for an additional 3 hours. The reaction mixture was poured into water and filtered to collect crystalline precipitate, washed with water and dried under reduced pressure to yield 0.8 g of a white powder of the title compound.

Preparation Example 5
1-amino-7-methoxyisoquinoline
A 8.0 g solution of 7-methoxyisoquinoline in 45 ml of N, N-dimethylaniline was raised to 60 ° C., and then 5.9 g of sodium amide was added. The reaction mixture was warmed to 130 ° C. over 2 hours and stirred for a further 1 hour under the same conditions. After cooling, the reaction mixture was poured into ice water and extracted with chloroform. The extract was washed with water and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel color chromatography and recrystallized from benzene to give 5.7 g of a colorless plate of the title compound.

Preparation Example 6
2'-methyl-2-bromoacetophenone
To a 3.0 g solution of 2'-methylacetophenone in 60 ml of acetic acid, 9.7 ml of 47% bromic acid and 8.6 g of pyridinium hydrobromide perbromide were added successively and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated sodium carbonate solution and then dried over anhydrous magnesium sulfate. The drying agent was filtered off and the solvent was removed under reduced pressure to yield 5.4 g of a colorless oily material of the title compound.

Preparation Example 7
2- (2-methylphenyl) imidazo [2,1-a] isoquinoline
A mixture of 3.0 g of -aminoisoquinoline, 6.7 g of 2'-methyl-2-bromoacetophenone and 17.5 g of sodium bicarbonate in 50 ml of ethanol was refluxed for 2 hours. After cooling, the reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel color chromatography and recrystallized from chloroform / petroleum ether to give 4.4 g of a light brown columnar material of the title compound.

Preparation Example 8
9-methoxy-2- (2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline
7.3 g of 2'-methyl-2-bromoacetophenone was added to a 3.1 g solution of 7-methoxy-3,4-dihydroisoquinoline in 40 ml of methylene chloride, and the mixture was stirred at room temperature for 4 hours and then under vacuum. Evaporated. To the resulting residue was added 2 ml of acetic acid and 10.4 g of ammonium acetate and the mixture was refluxed for 6 hours. After cooling, the reaction mixture was poured into 2N aqueous sodium hydroxide solution and extracted with ethyl acetate. The extract was washed with water saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to yield 0.7 g of a brown viscous material of the title compound.

Preparation Example 9
9-methoxy-5-methyl-2- (2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline
16 g of 2'-methyl-2-bromoacetophenone was added to a 12 g solution of 7-methoxy-3-methyl-3,4-dihydroisoquinoline in 120 ml of dimethoxyethane, and the mixture was stirred at room temperature for 14 hours. . The resulting white powder was collected by filtration to give 13 g of 7-methoxy-3-methyl-2- (2-methylphenyl) -3,4-dihydroisoquinolinium bromide. This white powder, 80 ml of acetic acid, and 12.8 g of ammonium acetate were then refluxed for 3 hours. After cooling, the reaction mixture was poured into water, basified by addition of saturated aqueous sodium carbonate solution and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give 5.3 g of a yellow oily substance of the title compound.

Preparation Example 10
9-methoxy-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline
Palladium (10% palladium) supported on activated carbon in a 4.9 g solution of 9-methoxy-5-methyl-2- (methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline in 30 ml of decalin 0.97 g was added and the mixture was refluxed for 6 h. After cooling and addition of 200 ml of chloroform, the mixture was filtered and the filtrate was evaporated in vacuo. The resulting residue was crystallized from hexane and ethyl acetate mixture (6: 1) to afford 3.0 g of the title compound.

Preparation Example 11
2- (2-methyl-3-thienyl) furo [3,2-c-] imidazo [1,2-a] pyridine
2- (5-bromo-2-methyl-3-thienyl) furo [3,2-c] imidazo [1,2-a] pyridine in 50 ml of tetrahydrofuran (according to a method similar to Preparation Example 7) Prepared by the reaction of 4-aminofuro [3,2-c] pyridine and 5-bromo-3-bromoacetyl-2-methylthiophene) a 6.1 g solution of lithium aluminum hydride in 50 ml of tetrahydrofuran Dropwise to a 3.5 g solution. After the addition was complete, the mixture was refluxed for 2 hours. After cooling, aqueous ether was added to decompose excess lithium aluminum hydride and the mixture was dried over anhydrous magnesium sulfate. The drying agent was filtered off and the solvent was removed under reduced pressure to yield 4.5 g of a white powder of the title compound.

Example 1
3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 3)
2.5 g of 2- (2-methylphenyl) imidazo [2,1-a] isoquinoline was dissolved in 30 ml of acetic acid and 6 ml of water with ice cooling and stirring. A small amount of a 3.4 g solution of sodium nitrite in 12 ml of water was added to the solution, and the mixture was stirred at room temperature for 1 hour. The crude crystals obtained were collected by filtration and washing. The powder obtained was suspended in a mixture of 30 ml of acetic acid and 15 ml of water. A small amount of 6.3 g of zinc powder was added to this suspension. After 1 h, the reaction mixture was filtered, 28% ammonia water was added to basify the filtrate and extracted with ethyl acetate, the extract was washed with water and saturated brine and dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate / petroleum ether to give 2.1 g of the title compound on orange needles.

Example 2
Hydrochloride of 3-amino-2- (2,5-dimethyl-3-furyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 271)
2- (2,5-dimethyl-3-furyl) imidazo [1,2-a] thieno [3,2-c] pyridine in 60 mL dioxane (4-aminothione according to a method analogous to Preparation Example 7 To a 4.0 g solution of no [3,2-c] pyridine and 3-bromoacetyl-2,5-methylfuran) 6 ml of isopentyl nitrite was added in small portions at 60 ° C. After the addition was complete, the mixture was stirred at 70 ° C. for an additional 20 minutes. After cooling, the precipitated crystals were collected by filtration, washed with ether, 40 ml of acetic acid and 30 ml of water were added under ice cooling, followed by 9.8 g of zinc powder. The mixture was stirred for 16 h. The solution was filtered, 28% ammonia water was added, the filtrate was basified and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give 3-amino-2- (2,5-dimethyl-3-furyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 271). 2.3 g of a pale yellow amorphous solid was obtained. A saturated solution of hydrogen chloride in ether was added to a 2.3 g solution of the product in 100 mL of ether, and the precipitated crystals were collected by filtration and recrystallized from ethanol to give 2.2 g of a pale yellow platy material of the title compound.

Example 3
The compounds obtained in the same manner as in Examples 1 and 2 are shown next.
Hydrochloride of 3-amino-2- (2-fluorophenyl) imidazo [2,1-a] isoquinoline (Compound 1)

3-amino-2- (2-chlorophenyl) imidazo [2,1-a] isoquinoline (Compound 2)


3-amino-9-fluoro-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 4)

3-amino-9-chloro-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 6)

3-amino-10-chloro-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 7)

3-amino-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 9)


3-amino-9-methyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 10)

3-amino-2- (2-methylphenyl) -7-propylimidazo [2,1-a] isoquinoline (Compound 13)

3-amino-6-isopentyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 15)

3-amino-6-methoxymethyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 16)

3-amino-2- (2-methylphenyl) -6- (phenoxymethyl) imidazo [2,1-a] isoquinoline (Compound 17)

3-amino-7-hydroxymethyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 18)

3-amino-9- (1-hydroxyethyl) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 19)

Hydrochloride of 3-amino-2- (2-methylphenyl) -9-phenylimidazo [2,1-a] isoquinoline (Compound 20)

3-amino-6- (4-methoxyphenyl) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 21)

3-amino-6-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 24)

3-amino-9-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 26)

3-amino-9-isopropoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 30)

3-amino-8,9-dimethoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 33)

3-amino-9-ethoxycarbonylmethoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 35)

3-amino-9- (2-hydroxyethoxy) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 36)

3-amino-9- (2-methoxyethoxy) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 37)

3-amino-6-benzyloxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 38)
9-acetoxy-3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 1)

3-amino-9-isobutyryloxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 43)

3-amino-9- (N, N-dimethoxycarbamoyloxy) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 44)

3-amino-7-benzylthio-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 45)

3-amino-2- (2-methylphenyl) -7- (methylthio) imidazo [2,1-a] isoquinoline (Compound 46)


6-acetyl-3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 47)

3-amino-7- (p-anisoyl) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 48)

Hydrochloride of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline-7-carboxylic acid (Compound 49)

3-amino-6-methoxycarbonyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 50)

3-amino-7-cyano-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 52)

3-amino-7-diethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 54)

3-amino-10-chloro-9-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 55)

3-amino-9-methoxy-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 56)

Hydrochloride of 3-amino-2- (3-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 57)

Hydrochloride of 3-amino-2- (2-ethylphenyl) imidazo [2,1-a] isoquinoline (Compound 59)

Hydrochloride of 3-amino-2- (2-trifluoromethylphenyl) imidazo [2,1-a] isoquinoline (Compound 60)

3-amino-2- (2,4-dimethylphenyl) imidazo [2,1-a] isoquinoline (Compound 62)

3-amino-2- (4-chloro-2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 66)


3-amino-2- (4-hydroxy-2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 68)

3-amino-2- (4-methoxy-2-methylphenyl) imidazo [2,1-a] isoquinoline (hydrochloride of compound 69))

Hydrochloride of 2- (4-acetoxy-2-methylphenyl) -3-aminoimidazo [2,1-a] isoquinoline (Compound 70)

3-amino-2- (24,6-trimethylphenyl) imidazo [2,1-a] isoquinoline (Compound 71)

3-amino-2- (3-methyl-2-thienyl) imidazo [2,1-a] isoquinoline (Compound 73)

3-amino-6-methoxy-2- (3-methyl-2-thienyl) imidazo [2,1-a] isoquinoline (Compound 74)

3-amino-9-methoxy-2- (3-methyl-2-thienyl) imidazo [2,1-a] isoquinoline (Compound 75)

3-amino-2- (4-methyl-2-thienyl) imidazo [2,1-a] isoquinoline (Compound 76)

3-amino-2- (3-ethyl-2-thienyl) imidazo [2,1-a] isoquinoline (Compound 77)

3-amino-2- (2-methyl-3-thienyl) imidazo [2,1-a] isoquinoline (Compound 78)

3-amino-2- (4-methyl-3-thienyl) imidazo [2,1-a] isoquinoline (Compound 81)

Hydrochloride of 3-amino-2- (2,5-dimethyl-3-thienyl) imidazo [2,1-a] isoquinoline (Compound 83)

3-amino-2- (2-chloro-3-methyl-4-thienyl) imidazo [2,1-a] isoquinoline (Compound 85)

3-amino-7-bromo-2- (2-chloro-3-methyl-4-thienyl) imidazo [2,1-a] isoquinoline (Compound 86)

3-amino-2- (3-methyl-2-furyl) imidazo [2,1-a] isoquinoline (Compound 88)

3-amino-2- (2,5-dimethyl-3-furyl) imidazo [2,1-a] isoquinoline (Compound 91)

3-amino-2- (1-methyl-2-pyrrolyl) imidazo [2,1-a] isoquinoline (Compound 94)

Maleic acid salt of 3-amino-2- (2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 96)

3-amino-9-fluoro-2- (2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 97)

Hydrochloride of 3-amino-8-chloro-2- (2-methylphenyl) 5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 98)

3-amino-9-bromo-2- (2-methylphenyl) 5,6-dihydroimidazo [2,1-a] isoquinoline

3-amino-5-methyl-2- (2-methylphenyl) 5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 100)

3-amino-9-methyl-2- (2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 102)

3-amino-5,5-dimethyl-2- (2-methylphenyl) 5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 104)

3-amino-6,7-dimethyl-2- (2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 105)

3-amino-2- (4-hydroxy-2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 107)

3-amino-2- (5-bromo-4-hydroxy-2-methylphenyl) -5,6-dihydroisoquinoline (Compound 108)

3-amino-5-methyl-2-phenylimidazo [2,1-a] thieno [3,2-c] pyridine (Compound 230)

3-amino-2- (2-hydroxyphenyl) -5-methylimidazo [2,1-a] thieno [3,2-c] pyridine (Compound 231)

3-amino-2- (2-chlorophenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 232)

3-amino-2- (2-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 234)

3-amino-8-bromo-2- (2-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 235)

3-amino-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 236)

3-amino-5-ethyl-2- (2-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 238)

3-amino-5,6-dimethyl-2- (2-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 239)

3-amino-5-methyl-2- (3-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 242)

3-amino-5-methyl-2- (2-trifluoromethylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 244)

3-amino-2- (2-methoxyphenyl) -5-methylimidazo [2,1-a] thieno [3,2-c] pyridine (Compound 245)

3-amino-2- (4-chloro-2-methylphenyl) -5-methylimidazo [2,1-a] thieno [3,2-c] pyridine (Compound 248)

3-amino-5-methyl-2- (2-thienyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 249)


3-amino-2- (3-methyl-2-thienyl) imidazo [1.2-a] thieno [3,2-c] pyridine (Compound 250)

3-amino-2- (2-methyl-3-thiethyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 254)

3-amino-5-methyl-2- (2-methyl-3-thienyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 255)

3-amino-2- (2,5-dimethyl-3-thienyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 264)

3-amino-2- (1-methyl-2-pyrrolyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 275)

3-amino-2- (2-methylphenyl) furo [3,2-c] imidazo [2,1-a] pyridine (Compound 276)

3-amino-2- (2-methyl-3-thienyl) furo [3,2-c] imidazo [2,1-a] pyridine (Compound 280)

3-imino-2- (2,5-dimethyl-3-furyl) furo [3,2-c] imidazo [2,1-a] pyridine (Compound 288)

Hydrochloride of 3-amino-7-methyl-2- (2-methylphenyl) imidazo [2,1-a] pyrrolo [3,2-c] pyridine (Compound 291)

Hydrochloride of 3-amino-7-benzyl-2- (2-methylphenyl) imidazo [2,1-a] pyrrolo [3,2-c] pyridine (Compound 292)

3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,4-c] pyridine (Compound 303)

3-amino-2- (2-methylphenyl) imidazo [1,2-a] thieno [2,3-c] pyridine (Compound 310)

3-amino-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] thieno [2,3-c] pyridine (Compound 311)

3-amino-8-methyl-2- (2-methylphenyl) imidazo [2,1-a] thieno [2,3-c] pyridine (Compound 312)

3-amino-2- (2-methylphenyl) furo [2,3-c] imidazo [1,2-a] pyridine (Compound 318)

3-amino-2- (2-methylphenyl) -5,6-dihydroimidazo [1,2-a] thieno [2,3-c] pyridine (Compound 323)

Example 4
3-Saethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 112)
3.0 ml of acetic anhydride was added to a 1.5 g solution of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 3) in 20 ml of ethanol. After 1 hour, the precipitated crude crystals were collected by filtration and recrystallized from ethanol to give 1.5 g of a white powder of the title compound.

Example 5
The compounds obtained in the same manner as in Example 4 are shown below.
3-acetylamino-2- (2-fluorophenyl) imidazo [2,1-a] isoquinoline (Compound 111)

3- (3-chloropropionylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 124)

2- (2-methylphenyl) -3- [3- (methylthio) propionylamino] imidazo [2,1-a] isoquinoline (Compound 125)

3-[(3-carboxypropionyl) amino] -2- (2,4-dimethylphenyl) imidazo [2,1-a] isoquinoline) (Compound 127)

3-hexanoylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 128)

3- (methoxyfumaroylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 129)

3- (p-anisoylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 131)

2- (2-methylphenyl) -3- (2-tenoylamino) imidazo [2,1-a] isoquinoline (Compound 132)

3-[(3-methyl-2-benz [b] furoyl) amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 133)

3-ethoxycarbonylamino-2- (2-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 355)

Example 6
Hydrochloride of 3- (N-acetyl-N-propylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 138)
6.0 g solution of 3-acetylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 112) in 250 ml of anhydrous N, N-dimethylformamide was dissolved in anhydrous N, N-dimethylformamide. To a 0.9 g solution of sodium hydride (pre-washed with hexane) in oil in 50 ml was added dropwise under a dry argon atmosphere at room temperature for 30 minutes. After stirring the mixture further for 1 hour, 2.2 ml of propyl bromide was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give a brown viscous material of 3- (N-acetyl-N-propylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 138) 11.0 g was obtained. A saturated solution of hydrogen chloride in ether was added to a solution of 3.0 g of ether in 100 ml of ether, and the precipitated crystals were collected by filtration. Recrystallization from ether / chloroform gave 2.7 g of a white powder of the title compound.

Example 7
The compound obtained by the same method as Example 6 is shown next.
3- [N-acetyl-N- (ethoxycarbonylmethyl) amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 134)


3- [N-acetyl-N- (N, N-diethylcarbamoylmethyl) amino] -2- (3-ethyl-2-thiethyl) imidazo [2,1-a] isoquinoline (Compound 135)

Hydrochloride of 3- [N-acetyl-N- (methoxyethyl) amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 136)

3- (N-acetyl-N-propylamino) -2- (2-fluorophenyl) imidazo [2,1-a] isoquinoline (Compound 137)

3- (N-acetyl-N-propylamino) -9-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 141)

3- (N-acetyl-N-propylamino) -2- (3-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 143)

3- (N-acetyl-N-propylamino) -2- (3-methyl-2-thienyl) imidazo [2,1-a] isoquinoline (Compound 144)

3- (N-acetyl-N-isopropylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 145)

3- (N-acetyl-N-allylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 146)

3- (N-acetyl-N-isopentylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 148)

3- [N-acetyl-N- (4-methylbenzyl) amino] -2- (methylphenyl) imidazo [2,1-a] isoquinoline (Compound 151)

3- [N-ethyl-N- [3- (methylthio) propionyl] amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 152)

2- (2,4-dimethylphenyl) -3-succinylaminoimidazo [2,1-a] isoquinoline (Compound 154)

Example 8
Hydrochloride of 3- (N-ethyl-N-propylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 207)
A solution of 4.0 g of 3- (N-acetyl-N-propylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 138) in 30 ml of anhydrous tetrahydrofuran was dissolved in anhydrous tetrahydrofuran. To a solution of 0.7 g of lithium aluminum hydride in 20 ml was added dropwise over 30 minutes. The mixture was stirred at rt for 4 h. Aqueous ether was added to decompose excess lithium aluminum hydride and then the mixture was dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to obtain 3.5 g of a yellow oily substance of 3- (N-ethyl-N-propylamino) -2- (methylphenyl) imidazo [2,1-a] isoquinoline (Compound 207). Obtained. A saturated solution of hydrogen chloride in ether was added to a 3.5 g solution of the product in 100 ml of ether, and the precipitated crystals were collected by filtration. Recrystallization from ether / chloroform gave 3.0 g of a white powder of the title compound.

Example 9
2- (2-methylphenyl) -3-[(1-phenylethyl) amino] imidazo [2,1-a] isoquinoline (Compound 192)
A 5.0 g solution of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 3) in 30 ml of anhydrous N, N-dimethylformamide was dissolved in anhydrous N, N-dimethylformamide 10 To a 1.2 g solution of sodium hydride (pre-washed with hexane) in oil in ml was added dropwise under dry argon atmosphere at room temperature for 30 minutes. After further stirring the mixture for 1 hour, a solution of 4.1 g of (1-bromoethyl) benzene in 30 ml of anhydrous N, N-dimethylformamide was added dropwise. After the addition was complete, the mixture was stirred at rt for 1 h. The solution was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography and recrystallized from benzene / hexanes to give 5.3 g of a colorless needle-like material of the title compound.

Example 10
A solution of 3.0 g of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 3) in 30 ml of anhydrous N, N-dimethylformamide was dissolved in anhydrous N, N-dimethylformamide 50 To a 0.9 g solution of sodium hydride (pre-washed with hexane) in oil in ml was added dropwise under a dry argon atmosphere at room temperature for 30 minutes. After stirring the mixture further for 1 hour, 1.0 ml of allyl bromide was added dropwise. The mixture was stirred at room temperature for 2 hours and then at 50 ° C. for 16 hours. The solution was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give 1.5 g of a brown oily material of 3-diallylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 223). Chromatography then gave 0.5 g of a brown oily material of 3-allylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 221).
The physicochemical data of 3-diallylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 223) is shown below.

The physicochemical data of 3-allylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 221) is shown below.

Example 11
3- (N, N-diethylcarbamoylmethyl) amino-2- (2-methylphenyl) imidazo in the same manner as in Example 10 except that N, N-diethylchloroacetamide was used instead of allyl bromide Brown oily substance of [2,1-a] isoquinoline (Compound 157) and 3- [bis (N, N-diethylcarbamoylmethyl) amino-2- (2-methylphenyl) imidazo [2,1- a] brown oily material of isoquinoline (Compound 198) was obtained. Saturated hydrogen chloride solution in ether was added to a 1.6 g solution of an electronic compound in 50 ° C. ether, and the precipitated crystals were collected by filtration. Tan powder of hydrochloride of 3- (N, N-diethylcarbamoylmethyl) amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 157) crystallized from ethyl acetate / chloroform 1.0 g was obtained.
The physicochemical data of the hydrochloride of 3- (N, N-diethylcarbamoyl methyl) amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 157) is shown below.

The physicochemical data of 3- [bis (N, N-diethylcarbamoylmethyl) amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 198) is shown below.

Example 12
3-amino-7-chloro-2- (2-methylphenyl) imidazo [2,1-a] instead of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline and allyl bromide 7-chloro-3-ethylamino-2- (2-methylphenyl) imidazo [2,1-a] in the same manner as in Example 10 except for using isoquinoline (Compound 5) and ethyl iodide. Yellow needle-like material of isoquinoline (compound 159) and colorless needle-like material of 7-chloro-3-diethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (compound 199) Obtained.
The physical and chemical data of 7-chloro-3-diethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 199) are shown below.

The physical and chemical data of 7-chloro-3-ethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 159) are shown below.

Example 13
3-amino-7-methoxycarbonyl-2- (2-methylphenyl) imidazo [2,1 instead of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline and allyl bromide -a] 3-Dimethylamino-7-methoxycarbonyl-2- (2-methylphenyl) imidazo [y], in the same manner as in Example 10 except that isoquinoline (Compound 51) and methyl iodide are used. A pale yellow powder of 2,1-a] isoquinoline (Compound 197) was obtained.

Example 14
Hydrochloride of 2- (2-methylphenyl) -3-piperidinoimidazo [2,1-a] isoquinoline (Compound 217)
4.6 g and 1,5- potassium carbonate in a 3.0 g solution of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 3) in 50 ml of anhydrous N, N-dimethylformamide 1.6 ml of dibromopentane was added continuously and the mixture was stirred at 140 ° C. for 3 hours. After cooling, the mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give 3.7 g of a brown oily material of 2- (2-methylphenyl) -3-piperidinoimidazo [2,1-a] isoquinoline (Compound 217). Saturated hydrogen chloride solution in ether was added to a 2.0 g solution of 80 g of ether and the precipitated crystals were collected by filtration. Recrystallization from ethyl acetate / petroleum ether gave 1.4 g of a white powder of the title compound.

Example 15
Hydrochloride of 2- (2-methylphenyl) -3-morpholinimidazo [2,1-a] isoquinoline (Compound 218)
A solution of 5.5 g of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 3) in 50 ml of anhydrous N, N-dimethylformamide was dissolved in anhydrous N, N-dimethylformamide 150 To a 1.8 g solution of sodium hydride (pre-washed with hexanes) in an oil in ml was added dropwise under a dry argon atmosphere at room temperature for 30 minutes. Further the mixture was stirred for 1 hour and then 3.2 g of bis (2-chloroethyl) ether was added dropwise. The mixture was stirred at room temperature for 2 hours and then at 60 ° C. for 2 hours. The solution was poured into ice water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to yield 2.0 g of a yellow oily substance of 2- (2-methylphenyl) -3-morpholinimidazo [2,1-a] isoquinoline (Compound 218). To a 2.0 g solution of the product in 80 mL of ether was added a saturated solution of hydrogen chloride in ether. The precipitated crystals were collected by filtration and washed with ethanol to give 1.1 g of an off-white powder of the title compound.


Example 16
3-4-methylbenzylideneamino) -2- (methylphenyl) imidazo [2,1-a] isoquinoline (Compound 225)
2.2 g of p-tolualdehyde was added to a solution of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (hwa 3) in 50 ml of methanol. The mixture was stirred at room temperature for 22 hours, poured into water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate / petroleum ether to give 5.4 g of yellow crystals of the title compound.

Example 17
3-[(1-bromo-2-naphthyl) methylideneamino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 228)
A yellow powder of the title compound was obtained in the same manner as in Example 16 except that 1-bromo-2-naphthylaldehyde was used instead of p-tolualdehyde.

Example 18
2- (2-methylphenyl) -3-propylideneaminoimidazo [2,1-a] isoquinoline (Compound 224)
The brown oily material of the title compound was obtained in the same manner as in Example 16 except that propylaldehyde was used instead of p-tolualdehyde.

Example 19
2- (2-ethylphenyl) -3- (4-methylbenzylideneamino) imidazo [2,1-a] isoquinoline (Compound 226)
3-amino-2- (ethylphenyl) imidazo [2,1-a] isoquinoline (Compound 59) was used instead of 3-amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline A yellow powder of the title compound was obtained in the same manner as in Example 16 except for the following.

Example 20
3- (4-methylbenzylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 194)
0.9 g of sodium borohydride was added to a 4.3 g solution of 3- (4-methylbenzylideneamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 225) in 50 ml of ethanol. . The mixture was refluxed for 2 hours, then poured into water and extracted with chloroform. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate.
The desiccant was filtered off and the solvent was removed under reduced pressure. The crude crystals were recrystallized from petroleum ether / chloroform to give 3.7 g of yellow needles of the title compound.

Example 21
3-ethylamino-9-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 167)
To a 5.0 g solution of 3-amino-9-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 26) in 100 ml of ethanol, 3.0 ml of acetaldehyde were added and the mixture was stirred at room temperature. Stir for hours. 3.3 g of sodium borohydride was added to the mixture and refluxed for 2 hours, and then the reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated brine and then dried over anhydrous magnesium sulfate. The desiccant was filtered off and the solvent was removed under reduced pressure. The crude crystals were recrystallized from petroleum ether / ethyl acetate to give 5.0 g of a colorless needle-like material of the title compound.


Example 22
The compounds obtained according to the same method as Examples 8, 9, 10 and 21 are shown next.
2- (2-methylphenyl) -3- (propoxycarbonylmethyl) aminoimidazo [2,1-a] isoquinoline (Compound 156)

Hydrochloride of 3-ethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 158)

Hydrochloride of 3-ethylamino-2- (2-methylphenyl) 7-propylimidazo [2,1-a] isoquinoline (Compound 163)

3-ethylamino-6-methoxymethyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 164)

3-ethylamino-7-hydroxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 165)

3-ethylamino-6-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 166)

7-benzyloxy-3-ethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 169)

7-ethoxycarbonyl-3-ethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 173)


3-ethylamino-2- (2-trifluoromethylphenyl) imidazo [2,1-a] isoquinoline (Compound 175)

3-ethylamino-6-methoxy-2- (3-methyl-2-thienyl) imidazo [2,1-a] isoquinoline (Compound 176)

2- (2-chloro-3-methyl-4-thienyl) -3-ethylaminoimidazo [2,1-a] isoquinoline (Compound 179)

Hydrochloride of 3- (2-methoxyethyl) amino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 180)

6-isopentyl-2- (2-methylphenyl) -3-propylaminoimidazo [2,1-a] isoquinoline (Compound 181)

6-methoxy-2- (2-methylphenyl) -3-propylaminoimidazo [2,1-a] isoquinoline (Compound 182)

Hydrochloride of 3-isopropylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 184)

2- (2-methylphenyl) -3-[(3-methylthiopropyl) amino] imidazo [2,1-a] isoquinoline (Compound 185)

2- (2-methylphenyl) -3- [3- (methylsulfinyl) propylamino] imidazo [2,1-a] isoquinoline (Compound 186)

3-isopentylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 188)

3-isopentylamino-2- (2,4-dimethylphenyl) imidazo [2,1-a] isoquinoline (Compound 189)

3-cyclopentylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 190)

3-hexylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 191)

3-[(1-bromo-2-naphthyl) methylamino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 195)

3-[(3-methyl-2-benz [b] furyl) methylamino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 196)

7-bromo-3-diethylamino-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 200)


Hydrochloride of 3- [N- (2-chloroethyl) -N-ethylamino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 202)

3-[(N-ethyl-N- [2-N, N-diethylamino) ethyl] amino] -2- (3-ethyl-2-thienyl) imidazo [2,1-a] isoquinoline ( Compound 203)

Hydrochloride of 3- [N-ethyl-N- (2-methoxyethyl) amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 205)

3- (N-ethyl-N-propylamino) -2- (2-fluorophenyl) imidazo [2,1-a] isoquinoline (Compound 206)

Hydrochloride of 3- (N-ethyl-N-propylamino) -6-isopentyl-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 208)

Hydrochloride of 3- (N-ethyl-N-propylamino) -2- (3-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 211)

3- (N-ethyl-N-propylamino) -2- (3-methyl-2-thienyl) imidazo [2,1-a] isoquinoline (hydrochloride of compound 212))

3- [N-ethyl-N- (3-methylthiopropyl) amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 214)

Hydrochloride of 3- (N-ethyl-N-isopentylamino) -2- (2-ethylphenyl) imidazo [2,1-a] isoquinoline (Compound 216)

3- [N-ethyl-N- (4-methylbenzyl) amino] -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 219)

3- [N-ethyl-N- (4-methylbenzyl) amino] -2- (2-ethylphenyl) imidazo [2,1-a] isoquinoline (Compound 220)

Hydrochloride of 3- (N-allyl-N-ethylamino) -2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 222)

Hydrochloride of 3-ethylamino-2- (2-methylphenyl) imidazo [1,2-a] thieno [2,3-c] pyridine (Compound 340)

Hydrochloride of 3-ethylamino-2- (2-methylphenyl) imidazo [1,2-a] thieno [2,3-c] pyridine (Compound 345)

Hydrochloride of 3- (N-ethyl-N-propylamino) -2- (2-methylphenyl) -5-methylimidazo [1,2-a] thieno [2,3-c] pyridine (Compound 356)

Example 23
3-amino-9-methoxy-2- (2-methylphenyl) -5,6-dihydroimidazo [2,1-a] isoquinoline (Compound 103)
Into a 8.4 g solution of 3-amino-9-methoxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 26) in 100 ml of ethanol, 1.0 g of activated carbon supported palladium (Pd 10%) was added. Was added. After introducing hydrogen, the mixture was stirred for 48 hours at room temperature. The reaction mixture was filtered and the filtrate was evaporated in vacuo. The resulting residue was purified by silica gel column chromatography and recrystallized from ethyl acetate / isopropyl ether to give 1.5 g of a pale yellow powder of the title compound.

Example 24
3-amino-9-hydroxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 22)
To a solution of 5.0 g of 3-amino-9-benzyloxy-2- (2-methylphenyl) imidazo [2,1-a] isoquinoline (Compound 40) in 100 ml of ethanol, 0.5 g of activated carbon supported palladium (Pd 10%) was added. Was added. After introducing hydrogen, the mixture was stirred at rt for 24 h. The reaction mixture was filtered and the filtrate was evaporated in vacuo. The resulting residue was purified by silica gel column chromatography and recrystallized from water / methanol to give 3.2 g of pale yellow needles of the title compound.

Pharmaceutical Formulation 1: Powder containing 3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [2,3-c] pyridine (Compound 236) as active ingredient
5 g of 3-amino-5-methyl-2- (2-methylphenyl) imidazo [2,1-a] thieno [3,2-c] pyridine (Compound 236) and 95 g of lactose were uniformly mixed to obtain powder. Prepared.
Pharmaceutical Formulation 2: Granules Containing 3-Amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 236) as Active Ingredient
5 g of 3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 236), 36 g of lactose, 31 g of corn starch and crystalline After 22 g of cellulose were mixed and the powder was granulated by kneading with 4 g of hydroxypropyl cellulose in 1000 ml of water, the obtained kernels were dried at 50 ° C. for 4 hours. The dried kernels were sieved in a 12 mesh sieve and mixed with 2 g of magnesium stearate to prepare granules.
Pharmaceutical Formulation 3: Tablets Containing 3-Amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 236) as Active Ingredient
5 g of 3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 236), 35 g of lactose, 32 g of corn starch and crystalline 24 g of cellulose were mixed and the powder was granulated by kneading with an aqueous solution containing 2 g of hydroxypropyl cellulose, and the granules were dried at 50 ° C. for 4 hours. The granules were mixed with 2 g of magnesium stearate and then compressed into tablets weighing 200 mg each using a tablet maker.
Pharmaceutical Formulation 4: Capsules Containing 3-Amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 36) as Active Ingredient My
5 g of 3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 236), 38 g of lactose, 33 g of starch, crystalline cellulose 22 g and 2 g magnesium stearate were mixed. The mixture was filled into hard gelatin capsules using a capsule filling machine to weigh 200 mg each.
Pharmaceutical Formulation 5: Syrups Containing 3-Amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (Compound 236) as Active Ingredient
3-amino-5-methyl-2- (2-methylphenyl) imidazo [1,2-a] thieno [3,2-c] pyridine (compound 236g), 1g, sucrose 30g, D-sorbitol (70w / v%) 25 g, 30 mg ethyl p-hydroxybenzoate and 15 mg propyl p-hydroxybenzoate were dissolved in 60 g of warm water. After cooling, the flavor dissolved in 150 mg of glycerin and 500 mg of ethanol (96%) was added. Water was added to the mixture to prepare 100 ml of syrup.

权利要求:
Claims (19)
[1" claim-type="Currently amended] Fused imidazo [1,2-a] pyridine, pharmaceutically acceptable salt or solvate thereof represented by the following general formula (I):

Where
Ring A and ring B independently of one another represent an aromatic ring selected from benzene, thiophene, furan and pyrrole rings,
R ₁ represents a hydroxyl group, a halogen atom, a lower alkyl group which may be halogenated, a lower alkoxy group or an acyloxy group,
R ₂ and R ₃ may be the same or different and each is hydrogen atom, alkenyl group, acyl group, alkoxycarbonyl group, or 1) halogen atom, 2) hydroxy group, 3) lower alkoxy group, 4) lower Lower alkyl groups which may have a substituent (s) selected from the group consisting of alkylthio groups, 5) alkylsulfinyl groups, 6) alkoxycarbonyl groups, 7) carbamoyl groups, 8) alkylamino groups and 9) aryl groups , Or
R ₂ and R ₃ together with the nitrogen atom to which they are attached may form a 5- or 6-membered monocyclic heterocyclic ring, or
R ₂ and R ₃ together with the nitrogen atom to which they are attached may form an alkylideneamino group or an arylalkylideneamino group,
R ₄ and R ₅ are each independently a halogen atom, cyano group, hydroxyl group, carboxyl group, alkoxycarbonyl group, acyl group, alkylamino group, aryl group, acyloxy group, carbamoyloxy group, or 1) Lower alkyl groups which may have a substituent (s) selected from the group consisting of hydroxyl groups, 2) lower alkoxy groups, 3) aryl groups and 4) aryloxy groups, or 1) hydroxyl groups, 2) lower alkoxy groups, A lower alkoxy group which may have a substituent (s) selected from the group consisting of 3) a lower alkoxycarbonyl group and 4) an aryl group, or a lower alkylthio group which may be substituted by an aryl group,
k represents 0, 1, 2 or 3,
m represents 0, 1 or 2,
n represents 0, 1 or 2,
Dotted lines represent single bonds or double bonds with solid lines,
Provided that a plurality of R ₄ 's may be bonded to the same carbon atom.
[2" claim-type="Currently amended] 2. Compounds according to claim 1, wherein ring B is a benzene ring and k is 1, 2 or 3.
[3" claim-type="Currently amended] _{3. A} substituent according to claim 2, wherein R ₂ and R ₃ may be the same or different, each of which is selected from a hydrogen atom, an alkenyl group, or a group consisting of a halogen atom, a lower alkoxy group, a lower alkylthio group and an aryl group ( Or a lower alkyl group which may have (s) or R ₂ and R ₃ together with the nitrogen atom to which they are attached may form a 5- or 6-membered monocyclic heterocyclic ring.
[4" claim-type="Currently amended] The compound of claim 1, wherein ring B is a thiophene, furan or pyrrole ring.
[5" claim-type="Currently amended] 5. The substituent according to claim 4, wherein R ₂ and R ₃ may be the same or different, each selected from a hydrogen atom, an alkenyl group, or a group consisting of a halogen atom, a lower alkoxy group, a lower alkylthio group and an aryl group ( Or a lower alkyl group, or R ₂ and R ₃ together with the nitrogen atom to which they are attached can form a 5- or 6-membered monocyclic heterocyclic ring.
[6" claim-type="Currently amended] 6. The compound of claim 5, wherein ring B is a thiophene or pyrrole ring.
[7" claim-type="Currently amended] The compound of claim 6, wherein ring B is a thiophene ring.
[8" claim-type="Currently amended] 8. The compound of claim 7, wherein k is 1, 2 or 3.
[9" claim-type="Currently amended] The compound of claim 1, wherein ring A is an aromatic ring selected from benzene, thiophene, furan and pyrrole rings; Ring B is a benzene or thiophene ring; R ₁ is a halogen atom or a lower alkyl group or lower alcohol group which may be halogenated; k is 1 or 2; R ₂ is a hydrogen atom; R ₃ is a lower alkyl group which may have a substituent (s) selected from a hydrogen atom, an alkenyl group, or a group consisting of a halogen atom, a lower alkoxy group, a lower alkylthio group and an aryl group.
[10" claim-type="Currently amended] The compound of claim 9, wherein the dotted line represents a double bond with a solid line.
[11" claim-type="Currently amended] The compound of claim 10, wherein ring A and the cyclic substituent (s) represent the following general formula:

Wherein R ₁ and R ₆ are each independently a halogen atom, a lower alkyl group which may be halogenated, or a lower alkoxy group;
k 'is 0 or 1;
Z is a hetero atom selected from sulfur, oxygen and nitrogen atoms.
[12" claim-type="Currently amended] 12. The compound of claim 11, wherein at least one R ₁ and R ₆ is a lower alkyl group.
[13" claim-type="Currently amended] 13. The compound of claim 12, wherein at least one of R ₁ and R ₆ is a lower alkyl group having 1 or 2 carbon atoms.
[14" claim-type="Currently amended] The compound of claim 13, wherein R ₆ is a lower alkyl group having 1 or 2 carbon atoms; R ₄ and R ₅ are each independently a substituent selected from a halogen atom, a lower alkyl group, a lower alkoxy group and a lower alkylthio group.
[15" claim-type="Currently amended] 15. The compound of claim 14, wherein ring B is of structural formula Benzene or thiophene ring represented by; R ₂ and R ₃ are hydrogen atoms; or a compound wherein k 'is 0 or 1.
[16" claim-type="Currently amended] 2. A ring according to claim 1, wherein ring A is an aromatic ring selected from benzene, thiophene, furan and pyrrole rings represented by the following general formula (I-A); Ring B is a benzene or thiophene ring represented by the following formula (I-B); R2 and R3 are hydrogen atoms; R 4 and R 5 are independently substituents selected from halogen atoms, lower alkyl groups, lower alkoxy groups or lower alkylthio groups; m is 0, 1 or 2; n is 0, 1 or 2; Compounds with dashed lines represent double bonds with solid lines:

From here,
k 'and Z are as defined above,
Substituent R ₁ on the ring is a halogen atom, a lower alkyl group which may be halogenated, or a lower alkoxy group.
[17" claim-type="Currently amended] A pharmaceutical composition containing a compound as defined in claim 1 together with a pharmaceutically acceptable carrier.
[18" claim-type="Currently amended] The pharmaceutical composition of claim 17, wherein the pharmaceutical composition is useful for treating gastrointestinal diseases.
[19" claim-type="Currently amended] The pharmaceutical composition of claim 17, wherein the pharmaceutical composition is useful as an antiulcer agent.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP4012246B2|2007-11-21|Chemical substance

---

EP0944631B1|2004-02-18|Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases

---

AU719392B2|2000-05-11|Nitrogen-containing heterocyclic compounds

---

JP5014551B2|2012-08-29|Β-carboline derivatives effective as phosphodiesterase inhibitors

---

EP1448560B1|2005-06-15|3-SUBSTITUTED OXINDOLE beta 3 AGONISTS

---

KR101084871B1|2011-11-21|Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

---

US4894456A|1990-01-16|Synthesis of camptothecin and analogs thereof

---

EP1735320B1|2009-06-17|Compounds and methods for treating dyslipidemia

---

US6087368A|2000-07-11|Quinazolinone inhibitors of cGMP phosphodiesterase

---

TWI359814B|2012-03-11|Novel heterocyclic compounds useful for the treatm

---

US7968564B2|2011-06-28|HIV integrase inhibitors

---

DE60315615T2|2008-10-02|Tricyclic compounds based on thiophes and medicaments comprising them

---

US7265127B2|2007-09-04|β3 adrenergic agonists

---

AU707055B2|1999-07-01|Tetracyclic derivatives, process of preparation and use

---

RU2267490C2|2006-01-10|Derivatives of substituted pyrrolopyridinone useful as phosphodiesterase inhibitors

---

AU690140B2|1998-04-23|Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents

---

DE60302336T2|2006-08-03|New pyridine and quinoline derivatives

---

FI79846C|1990-03-12|Process for the preparation of pharmacologically valuable heteroaromatic amine derivatives

---

US5122526A|1992-06-16|Camptothecin and analogs thereof and pharmaceutical compositions and method using them

---

US4981968A|1991-01-01|Synthesis of camptothecin and analogs thereof

---

JP4145492B2|2008-09-03|Tetrahydropyrido ether

---

AU751486B2|2002-08-15|Fused pyridine inhibitors of cGMP phosphodiesterase

---

RU2136682C1|1999-09-10|Imidazopyridines, method of their synthesis, pharmaceutical composition on said and method of pharmaceutical composition preparing

---

DE60214359T2|2007-08-30|Nitrogen-based camptothecine derivatives

---

ES2693247T3|2018-12-10|Derivative of tetrahydrocarboline

同族专利:

---

公开号 | 公开日

---

AU698867B2|1998-11-12|

---

US6020342A|2000-02-01|

---

EP0822194A4|1998-04-29|

---

EP0822194A1|1998-02-04|

---

CN1295071A|2001-05-16|

---

US6103736A|2000-08-15|

---

CN1182428A|1998-05-20|

---

CN1064360C|2001-04-11|

---

CA2218705A1|1996-10-24|

---

AU5287296A|1996-11-07|

---

WO1996033195A1|1996-10-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1995-04-21|Priority to JP97130/1995

---

1995-04-21|Priority to JP9713095

---

1996-04-10|Application filed by 다나까 테츠오, 신니폰 야꾸힝 가부시키 가이샤

---

1999-01-25|Publication of KR19990007836A

优先权:

---

申请号 | 申请日 | 专利标题

---

JP97130/1995|1995-04-21|

---

JP9713095|1995-04-21|